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ABSTRACT

Self-stabilizing polyacrylate nanoparticle emulsions were previously investigated in the Turos
laboratory, and provided a new model for delivering antibiotics via encapsulation or covalent
binding of the desired bioactive compound within the polymer nanoparticles. The method used
the in water, free radical emulsion polymerization of butyl acrylate/styrene mixture to form the
polymer chain stabilized with a surfactant. Current research in this dissertation further explores
the versatility of related nanoparticle emulsion systems. Chapter 2 provides an overview of the
loading of certain therapeutic drugs, such as 5-aminosalicylic acid and derivatives thereof, for
the treatment of irritable bowel syndrome. Chapter 3 explores homo-polymer nanoparticle
emulsions composed of menthyl acrylate as the monomer. Thereby obviating the need for a
copolymer emulsion polymerization. The homo(menthyl acrylate) nanoparticle emulsion
provided greater stability compared to the previous copolymer models. The resulting
homopolymer emulsion exhibited a decrease in cytotoxicity, and a 400% increase for loading of
penicillin G. Chapter 4 explores novel polyacrylamide nanoparticle emulsion using only Nacrylated ciprofloxacin to form a homo-polymer polyacrylate nanoparticle emulsion, thereby
requiring no additional co-monomers. The resulting emulsion has a relatively low cytotoxicity
with similar bioactivity to free ciprofloxacin.

xi

CHAPTER ONE

THE USE OF NANOPARTICLES FOR THE DELIVERY OF BIOACTIVE COMPOUNDS

1.1 Introduction to Synthesis of Nanoparticles
The topic of nanomaterials encompasses a vast variety of fields of study. Nanomaterials can be
made from inorganic, organic, and hybrid materials and are 1-1000 nm in size. Some inorganicbased materials and applications include carbon nanotubes in composite materials and electronic
circuit boards; nano-silver in textiles and food packaging; nano-titanium dioxide in cosmetics,
creams, and paints; nano-cerium oxide as a fuel additive; nano-iron used to form smart fluids,
and magnetically responsive materials.1-3

The main focus of this review will be towards the drug delivery, antibacterial, and medicinal
applications of nanomaterials, which can be used for loading bioactive compounds into
nanospheres, nanocapsules, and nanoparticles.

1.1.1 Nanoparticles for the Delivery of Bioactive Compounds
The loading of bioactive compounds within or on the surface of nanoparticles for delivery are
typically achieved through one of three basic models as depicted in Figure 1.1. In the first model,
the bioactive compound is attached to the exterior surface of the nanoparticles. In the second

1

model, the bioactive compound is bound to the interior surface or within the matrix of the
nanoparticle. In the last model, the desired compound is encapsulated/entrapped within the
nanoparticle without physical attachment.4

Figure (1.1) Three models for nanoparticle drug-loading.

1.1.2 Synthesis of Drug-Loaded Nanoparticles
The following techniques encompass the typical synthetic methods used for the formation of
drug-carrying nanoparticle polymers, which include poly(alkyl cyanoacrylates), poly(styrenebutyl acrylates), poly(lactic acid), poly(lactide-glycolides), poly(glycolide), chitosan, gelatin, and
sodium alginate.

2

1.1.2.1 Polymer Dispersion Technique

Figure (1.2) Visualization of solvent evaporation nanoparticle formation.

Figure 1.2 illustrates the general method of nanoparticle formation using the solvent evaporation
method. The polymer and bioactive compound are mixed together, and dissolved in an organic
solvent with a relatively low boiling point compared to water. The polymer, bioactive compound,
and organic solvent mixture are further stabilized through the addition of surfactants. The
organic solvent is slowly evaporated via heating, vacuum, or continuous stirring. 5,6 Other
polymer dispersion techniques maintain the organic solvent within the micelle without
evaporation as a mode of loading hydrophobic material and drugs. The carrier solvent can be
visualized as an oil droplet stabilized by the surfactant within the aqueous solution and
maintained in suspension.

3

1.1.2.2 Monomer Polymerization Technique

Figure (1.3) Illustration of polymerization of monomers for the synthesis of nanoparticle
emulsions.

Figure 1.3 illustrates a different method of nanoparticle synthesis involving the dissolution of the
bioactive compound into the monomer mixture. The mixture is then suspended into an aqueous
solution via the use of surfactants and emulsifiers. Polymerization of the monomers is induced
and the resulting nanoparticles remain suspended within the solution. 7-9 Alternatively, the
bioactive compound can be incorporated into the nanoparticles via adsorption postpolymerization. The formation of the polymer inside the micelle formed by the surfactant allows
for a more stable structure compared to the free monomers.

4

1.1.2.3 Ionic Gelation Technique

Figure (1.4) Ionic interaction between chitosan and sodium tripolyphosphate.

The third common method of nanoparticle formation uses the transition of a liquid polymer
solution into a gel. The hydrophilic polymer (chitosan, gelatin, or sodium alginate) is mixed with
stirring into a solution of sodium tripolyphosphate. 10,11 The negatively charged sodium
polyphosphate and the positively charged ammonium group of the hydrophilic polymer cause the
5

gelation to form as illustrated in Figure 1.4. The entrapment of the bioactive drug occurs through
the addition of the drug to the hydrophilic polymer solution.

1.2 Polyacrylate Nanoparticles

1.2.1 Poly(Styrene-Butyl Acrylate) Nanoparticles
In 2007 the Turos laboratory provided a synthetic procedure for the formation of covalentlybound polyacrylate nanoparticle emulsions. The nanoparticle emulsion can carry and deliver
bioactive compounds, specifically, β-lactams. In addition, the nanoparticle delivery vehicle
affords additional shielding from degradative enzymes, and may serve as a new method for
delivering anti-MRSA (methicillin-resistant Staphylococcus aureus) compounds.9
In order to form the antibiotic-conjugated polyacrylate nanoparticles, the acryloyl derivative of
different β-lactams (Figure 1.5) was synthesized and used as a monomer for the nanoparticle
polymerization procedure.

Figure (1.5) O-Acrylated N-thiolated β-lactams used to prepare polyacrylate nanoparticles
6

The polyacrylate nanoparticle emulsion is prepared by emulsion polymerization in water. Figure
1.6 shows the general scheme for the formation of the nanoparticle emulsion. The resulting
nanoparticles had an average diameter between 30 and 50 nm. The olefin monomers are
segregated into micelles via the addition of sodium dodecyl sulfate as the surfactant. The
polymerization uses potassium persulfate as the radical initiator. The β-lactam bound
nanoparticle emulsions exhibited a 2 to 4 fold increase in antimicrobial activity against both
Staphylococcus aureus and β-lactam-resistant Staphylococcus aureus, when compared to the free
non-nanoparticle compound.

Figure (1.6) General scheme for preparing polyacrylate nanoparticle emulsions by free radical
emulsion polymerization.

The Turos laboratory later that year published another paper detailing the covalent binding of
various acrylated derivatives of penicillin as seen in Figure 1.7. It was also found that nonacrylated derivatives such as penicillin G were successfully encapsulated without covalent
attachment to the polymer backbone (Figure 1.8).

7

Figure (1.7) Acrylated derivatives of penicillins used for covalent binding in nanoparticle
emulsions.

Figure (1.8) Penicillin G and an esterified derivative used for encapsulation in nanoparticle
emulsions.

The antibacterial assays found that the minimum inhibitory concentration values for all drugloaded nanoparticles were similar against both Staphylococcus aureus and methicillin-resistant
Staphylococcus aureus. Kirby-Bauer assays using the penicillinase enzyme demonstrated the
ability of the nanoparticle to protect the penicillin framework against hydrolytic degradation. 12
8

In 2009, an additional study was published by the Turos group that compared the effects of
replacing sodium dodecyl sulfate in the emulsion polymerization procedure with other
surfactants. Prior research determined that the cytotoxicity of some of the emulsions was due to
excess surfactant (sodium dodecyl sulfate) used for emulsion polymerization, and the resulting
emulsions required further purifications in order to reduce cytotoxicity. The investigation
compared the effects of anionic, cationic, zwitterionic, and non-ionic surfactants on nanoparticle
formation and cytotoxicity. It was determined that non-ionic surfactants reduced the cytotoxic
properties of the resulting emulsions, and that all ionic surfactants exhibited an increase in toxic
properties of the emulsions.13 The cationic surfactant was the most cytotoxic.

1.2.2 Poly(Alkyl Cyanoacrylate) Nanoparticles
The formation of nanospheres using cyanoacrylate monomers were initially reported in 1979 by
Couvreur et al. and demonstrated the use of methyl cyanoacrylate and ethyl cyanoacrylate as
monomers. Nanospheres were produced by dropwise addition of the cyanoacrylates into HCl
solution (pH 2-3) containing Tween 20 as the surfactant. 14

Figure (1.9) The structure of poly(alkyl cyanoacrylate) polymers.

9

The resulting nanospheres provided an ideal model for the loading of some bioactive
compounds, and the field of poly(alkyl cyanoacrylate) nanoparticles has expanded tremendously
since then (Figure 1.9). The concentration of surfactant directly influences the size of the
nanospheres (50-300 nm). The molar masses of the resulting nanospheres were dependent on the
type of monomer and surfactant used.15,16

Poly(alkyl cyanoacrylate) nanoparticles can also form nanocapsules with the ability to load both
hydrophilic or hydrophobic bioactive compounds. Water containing nanocapsules suspended in
oil are able to deliver hydrophilic compounds, while oil containing nanocapsules suspended in
water are able to deliver hydrophobic compounds. 17

Figure (1.10) Antibiotics loaded into poly(alkyl cyanoacrylate) nanoparticles.

10

Figure 1.10 shows a few examples of antibiotics that were loaded up to 8.1% for amoxicillin,
90% for ampicillin, 16% for ciprofloxacin, and 44.6% for moxifloxacin, all as % weight of the
poly(alkyl cyanoacrylate) nanoparticles that successfully served as drug delivery vehicles. 18-21

1.3 Chiral Drug Delivery Vehicles
Chiral nanoparticles and chiral polymer materials have the potential for enantiodiscrimination. 22
One such study demonstrated the ability of enantiomeric and diastereoisomeric end groups
(Figure 1.11) of nanoparticles to exhibit different binding affinities towards protein targets. 23

Figure (1.11) Examples of chiral end groups of gold nanoparticles.

Organic-based chiral nanoparticles, such as green fluorescent protein chromophore nanoparticles
and poly(ethylene glycol)-modified thiolated gelatin nanoparticles, have also found uses in the
fields of photonics, sensing, recognition, DNA delivery, and non-linear optics. 24,25 It is rather
interesting that organic chiral nanoparticles exhibit optical and electronic properties, typically

11

expected from inorganic-based nanoparticles. These properties are usually dependent on
nanoparticle size, intermolecular interactions, and nanoparticle surface interactions. 26

In recent years, new models of chiral drug delivery vehicles have been more extensively
researched, and may provide viable methods for delivering bioactive compounds.

1.3.1 Layered Double Hydroxides as Chiral Drug Delivery Vehicles
In 2012, the Pingxiao Wu research group developed an interesting method for preparing chiral
nanoparticles for drug delivery.27 In this project the unstable chiral drug L-alanyl- L-glutamine
(L-(Ala-Glu)) was incorporated into the layered double hydroxides (LDHs). LDH
nanocomposites are layered structures of hydroxides, metal cations, and intercalated anions. The
layer sequence is typically composed of hydroxide anion/metal cation/hydroxide
anion/intercalated anion/hydroxide anion/metal cation/hydroxide anion. After several
experiments and computational studies, it was possible to characterize the structure of the
nanoparticles and also their properties. The principal problem with the employment of (L-(AlaGlu)) as a drug on its own is that it cannot maintain its morphology under the irradiation of UV
light. LDHs provide a protection for the (L-(Ala-Glu)) avoiding the change in its morphology
even under the irradiation of UV light. The LDHs appear to be useful for a wide variety of chiral
drugs as a drug delivery system.

1.3.2 Molecularly Imprinted Polymers (MIP) for Chiral Drug Delivery
In 2015, a remarkable work in the field of molecular imprinted polymers (MIPs) was published
Suksuwan et al.28 Figure 1.12 shows that the MIPs have the ability to create templated cavities,
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with the polymer surface, using the target molecule as the template. This technique mimics the
natural processes which produce polymers employing natural building blocks.

Figure (1.12) General scheme of MIPs

In this specific study the MIPs were designed to serve as an enantioselective receptor of (R)thalidomide. When the MIPs are loaded with the bioactive compound, the final objective is the
liberation of the drug into cancer cells. MIPs can be considered as an assembly of nanoparticles
using covalent binding and intermolecular forces for their formation. Using different
polymerization methods it was possible to control the diameters of the nanoparticles at uniform
sizes of 100 nm.

One important benefit of MIPs as host of (R)-thalidomide is the elimination of racemization of
the chiral drug, avoiding the formation of the (S) enantiomer that has toxic secondary effects.
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1.3.3 Chiral Drug Delivery via Chiral Mesoporous Silica (CMS)
Chiral mesoporous silica (CMS) can be successfully synthesized employing chiral surfactants as
templates. Starting with amorphous chiral silica materials, chiral directing reagents, such as
chiral surfactants and chiral metal complexes, can be added to distort the chirality of the
tetrahedral structure of SiO4. Among the many structural characteristics that CMS hold, their
helical mesoporous channels and chiral pore formation allow for enantioselective properties.
These properties have been extensively studied by many research groups. 29 The rate of drug
release is affected by the size of the pores (the larger the pore, the more rapid is the drug delivery
rate).

A chiral block copolymer can be imprinted through molecular techniques, acting as a template in
which an enantioselective separation can take place. The target enantiomers have different
affinities towards the chiral binding sites of this imprinted copolymer, permitting chiral
recognition. These materials have been proven to be able to enantioselectively absorb chiral
drugs.

In 2010, Yanhui-Yang et al. reported the synthesis of a new type of CMS materials in which the
use of an enantiopure surfactant was no longer necessary.30 Conventional achiral templates and a
chiral cobalt complex as a co-template were utilized to create the chiral environment in the
mesoporous silica. Vibrational circular dichroism measurements proved the chirality of the
CMS. These CMS materials, as carriers, were employed to control the enantioselective release of
metoprolol (Figure 1.13), a chiral drug. The pore diameter and structure played a decisive role in
the release profiles of the drug. Moreover, R- and S- enantiomers of metoprolol exhibited
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different rates in the delivery using these chirally-imprinted CMS materials in comparison with
their achiral CMS analogues (ACMS).

Figure (1.13) Structure of (S)-metoprolol and (R)-metoprolol.

Five years later, in 2015, the group of Sanming Li found a method to grow CMS using
biomimetic synthesis.31 In this work, B-CMS was prepared using N-palmityl-L-alanine (N-PLA)
as the chiral surfactant template, 3-aminopropyltriethoxysilane (APTES) as the co-structure
directing agent (CSDA) and tetraethoxysilane (TEOS) as the silica source. pH influenced the
energetics of the self-assembly process of three types of chiral mesoporous silica (B-CMS1, BCMS2 and B-CMS3). The particle length was determined by the stirring rate.

1.4 Antibacterial Polymers
The field of antibacterial polymers encompasses a wide variety of methods for the control of
bacterial contamination. Antibiotic polymers are formed via the polymerization of the bioactive
monomers, covalently binding the antibiotic to a polymer using non-bioactive co-monomers such
as styrene/butyl acrylate.
Optimal antibacterial polymer activity is reliant on the molecular weight of the final polymer,
with an ideal weight range of 1.4x104 Da to 9.4x104 Da. This effect is attributed with the
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increased difficulty in diffusing through the bacterial cell wall and delivering the active
compound into the cytoplasm. Some research has demonstrated that shorter chain polymers
exhibit a decrease in bioactivity compared to similar larger chain antibacterial polymers. The
authors attributed the effects to the ability of larger chain polymers to aggregate on the bacterial
cell wall and thus allow for better adsorption of the related antibacterial compound through the
bacterial membrane. Though the shorter chain polymers would presumably provide for better
diffusion through the cell wall, larger chain polymers may have an increased interaction with the
bacterial cell wall and thus improved minimum inhibitory concentration values. 32, 33

The counter ion charge on the polymer or polymer carrying particle also attributes to the ability
to deliver the desired drug to its target. Weaker ion pairing between the bioactive compound and
the carrier polymer allows for the drug to exist closer to its free state and thus interact with the
bacteria more readily.

Though the field of antibiotic delivery via the use of polymers is vast, examples of homopolymer
based antibacterial polymers are limited, and fewer still are examples where the polymer is
solely composed of antimicrobial monomers.

1.4.1 Homopolymer Antibacterial Polymers
Figure 1.14 shows the structure of an antibacterial monomer in which the bioactivity was
compared to that of the free monomer, the homopolymer, and the copolymer made with styrene.
Both the homopolymer and the styrene-co-polymer were successfully synthesized using radical
polymerization using benzoyl peroxide as radical initiator and toluene as the solvent. However,
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the biological assay against S. aureus showed a decrease in activity of both the homopolymer
and the styrene-co-polymer compared to the free monomer.34

Figure (1.14) 2, 4, 4’-trichloro-2’-hydroxydiphenyl ether derivative used as a monomer in
homopolymer formation.

Figure (1.15) 8-Hydroxyquinoline derivative used as a monomer for homopolymerization and
copolymerization with N-vinylpyrrolidone.

Figure 1.15 shows another example of an acrylated derivative of a bioactive compound
derivative used in homopolymer formation to test against bacteria. The acrylate monomer was
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polymerized with the co-monomer N-vinylpyrrolidone. Both the homopolymer and copolymer
were successfully synthesized using radical polymerization and an ethanol/buffer solution as the
solvent medium, and later isolated. The bioassay found that the homopolymer and copolymer
had a decrease in antibacterial activity relative to the acrylated monomers. 35

Figure (1.16) p-Vinylbenzyl tetramethylene sulfonium tetrafluoroborate used in the formation of
an antibacterial homopolymer.

Figure 1.16 shows the monomer used for the homopolymerization of a sulfonium-based
antibacterial polymer. The biological assay carried out against S. aureus and E. coli
demonstrated the homopolymer had increased bioactivity compared to the free monomer. This
was likely due to the increased concentration of the antibacterial moiety at the cell membrane,
thus allowing the cationic moiety to freely interact with the cell membrane. 36
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Figure (1.17) Thiadiazol derivative used for the formation of antibacterial homopolymers.

The thiadiazol acrylate derivative in Figure 1.17 was one of only two compounds that were
successfully homopolymerized in the published study via radical polymerization using benzoyl
peroxide as radical initiator and 1,4-dioxane as the solvent.37 The bioassay indicated the
homopolymer was effective against E. coli, while the monomer was much less bioactive. The
reason for the increase in bioactivity was not understood, and additional tests are required in
order to better understand the mode of action.
O
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Figure (1.18) Norfloxacin derivative used in the synthesis of poly(acrylated quinolone).

The acrylated quinolone in Figure 1.18 was used as a monomer in a radical polymerization
technique to prepare a homopolymer of an antibiotic acryloyl derivative. Both the monomer and
the homopolymer demonstrated excellent antibacterial activity with similar results against both
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gram-positive (S. aureus, B. subtilis, M. luteus) and gram-negative (E. coli) bacteria. However,
the testing was limited to the shake flask method of bioassay, due to the insolubility of the
polymer in water. This method measures the number of bacterial cell in suspension, then the
bioactive compound (suspended in phosphate buffer solution) is added to the bacterial
suspension and shaken, after 24 hours of incubation the number of bacterial cells in suspension is
counted and reported as % cell number reduction. In addition the formed polymer is very rigid
and brittle and thus has to be compounded with other processed polymers for administration and
assays.38

1.5 Dynamic Light Scattering and Zeta Potential Measurement of Nanoparticles
Dynamic light scattering measurements were used to determine the size of the nanoparticles
within the emulsions. The average size and surface charge of the emulsion was analyzed using a
Malvern Zetasizer nano-ZS instrument. Approximately 1 ml of the nanoparticle emulsion are
loaded into the Malvern disposable folded capillary cell DTS-1070. Each sample was analyzed in
triplicate, and each data collection consisted of 1 run of 20 scans (for size analysis) and 3 runs of
100 scans (for zeta potential determination).

A single measurement run averages 20 scans for size measurement; the data is displayed as an
intensity graph providing data for the nanoparticles within and if the samples contains multiple
peaks (polydispersion) or a single peak (monodispersion). The measurement recorded is the
value of the prominent peak (peak 1) within the graph. The runs are performed in triplicate and
the data was overlapped and averaged as seen in Figure 1.19.
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Figure (1.19) Sample graph of size data from dynamic light scattering.

Figure (1.20) Sample graph of zeta potential data from dynamic light scattering.
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For zeta potential measurements the instruments performs 3 runs consisting of 100 scans each. A
single measurement run averages 100 scans for zeta potential measurement; the data is displayed
as an intensity graph providing data for the detected –mV of the electrical double layer.
Electrical double layer values greater than 30mV are considered stable. The measurement
recorded of the zeta potential reading within the graph. The runs are performed in triplicate and
the data was overlapped and averaged as seen in Figure 1.20.

1.6 Exploring Poly(Styrene-Butylacrylate) Nanoparticle Emulsions
Chapter 2 explores and studies the synthesis, drug loading, and properties of poly(styrenebutylacrylate) nanoparticle emulsions. The aim is to diversify the drug loading capabilities of the
nanoparticle emulsions, and expand beyond antibiotics. To study the therapeutic viability of
poly(styrene-butylacrylate) nanoparticles emulsion, 5-aminosalicylic acid was loaded into the
nanoparticles via emulsion polymerization. Resulting emulsions were characterized using
dynamic light scattering, scanning electron microscope, in vitro cytotoxicity, and in vitro
antibacterial activity.
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CHAPTER TWO

POLYACRYLATE NANOPARTICLE EMULSIONS: A METHOD OF DELIVERING ANTIINFLAMMATORY COMPOUNDS

2.1 Introduction
Inflammatory bowel disease (IBD) is a collection of human health conditions that cause
inflammation in the large and small intestines. The two main IBDs are Crohn’s disease and
ulcerative colitis. Others include collagenous colitis, lymphocytic colitis, ischaemic colitis,
diversion colitis, Behcet’s syndrome, infective colitis, and indeterminate colitis. The site of
inflammation for Crohn’s disease is in the terminal ileum, while ulcerative colitis occurs mainly
in the colon and rectum. Since these conditions effect the intestinal lining they also tend to
interfere with the absorption of nutrients, and the proper disposal of toxins, thus causing liver
problems, arthritis, eye problems, and skin conditions. The symptoms are abdominal pain,
vomiting, diarrhea, hematochezia, weight loss, arthritis, pyoderma gangrenosum, and primary
sclerosing cholangitis. Typically IBDs are not fatal, however, they can reduce the quality of life
severely. In addition to disturbing the normal functions of the intestine, IBDs also dramatically
increase the risk for colorectal cancer. Most commonly the disease is diagnosed by performing a
colonoscopy along with a biopsy of pathological lesions.39-42
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One possible reason for the development of the condition is the presence of too much hydrogen
peroxide within the digestive tract, which has oxidative effects. The high concentration of
hydrogen peroxide causes the colonic barrier to become weaker, allowing antigenic material to
seep through the colonic barrier and cause an inflammatory reaction. This in turn leads to a
release of cytokines (tissue destroyers) and additional hydrogen peroxide. Being a self-defense
mechanism to rid the area of bacteria, this response causes a loop cycle because the additional
hydrogen peroxide brings on additional inflammation, and so on. As the intestinal barrier
becomes weaker, it becomes easier for bacteria to infiltrate.

2.2 Therapeutics for Inflammatory Conditions
Inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis have been common
especially among Europeans and North Americans. The physiological cause of the IBDs is not
clearly understood yet. Studies indicate that certain bacteria such as salmonella, yersinia,
shigella, and different strains of E.coli might be involved, as well as Helicobacter pylori and
Clostridium difficile.39,40 Corticosteroids and salicylates are frequently used therapeutic agents
for relieving symptoms of IBDs.

Figure (2.1) 5-Aminosalicylic acid (5-ASA), compound 1.
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5-Aminosalicylic acid (5-ASA) in Figure 2.1 is an active ingredient of agents used for the longterm maintenance therapy to prevent relapses of Crohn’s disease and ulcerative colitis. 5-ASA is
the choice drug for patients with mild to moderate IBD. The current average effective dose is 4.8
grams daily. In addition, studies have shown that as the amount of the therapeutic drug is
increased, the response in treatment is greater. However, the side effects also increase. There has
been a significant amount of research into developing additional derivatives of 5-ASA in order to
increase its effectiveness. The majority of the drugs developed aim to control the release, and
increase the delivery, of 5-ASA to the site of the disease; a common problem is that the further
the drug moves along the gastrointestinal tract, the less effective it becomes. Thus it is important
to develop a carrier for the drug that is time-released, in addition to protecting the active drug
from the intestinal environment until it reaches the desired point. 43

2.3 Mode of Action of 5-ASA
5-ASA is not absorbed into the body; it mainly works by providing relief at the site of the
inflammation, reducing the synthesis of inflammatory mediators known as eicosanoids (Figure
2.2) and inflammatory cytokines (specifically interleukin-23).44 As an inhibitor 5-ASA functions
as an antioxidant, and a free-radical eliminator. Eicosanoids analogs differ by containing various
hydroxyl, epoxide, and alkene functional groups. Eicosanoids are extremely oxidative, and 5ASA is postulated to possibly neutralize its effects. In addition, 5-ASA interacts with the
receptor PPAR- and induces an up-regulation of its expression. The function of PPAR- is to
reduce the inflammatory response caused by colitis.45
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Figure (2.2) Eicosanoid core structure.

2.4 Preparation of Nanoparticle Emulsions
Liposomes and nanoparticles are sometimes used as drug delivery vehicles in order to increase
and improve efficacy, bioavailability, and specificity of pharmaceutical compounds. Some of the
more notable examples include antibiotic-encapsulated polymeric nanoparticles and liposomes,
biodegradable nanospheres, and surface-coated gold nanoparticles.46-51 However, most of the
research in this area has been concentrated on anti-cancer agents, and only recently,
antibacterials. The Turos laboratory has developed polymer-bound drug nanoparticles for
antibacterial applications, and shown that the bio-activity of the drug-containing nanoparticles
can be more than the free drug. However, there has been very little focus on drug delivery for
IBD therapeutic agents. In the present study we aim to synthesize the nanoparticle-bound 5-ASA
nanoparticles, and to characterize them and check their bio-activity in comparison with the free
drug. A derivative of 5-ASA, compound 2 (Figure 2.3), was synthesized to test the covalentlybound drug polyacrylate nanoparticle emulsions. Another derivative of 5-ASA, compound 3
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(Figure 2.4), was synthesized to test the drug encapsulation model of polyacrylate nanoparticles
emulsions.

H
N

COOH

O
OH
Compound 2

Figure (2.3) 5-Acryloylamino-2-hydroxybenzoic acid, compound 2.

Figure (2.4) 5-Acetylamino-2-hydroxybenzoic acid, compound 3.

The basic concept is to attach the anti-inflammatory drug covalently to the nanoparticle. To do
this, the first step is to add an acryloyl group to a convenient functionality on the free drug, such
as the amino group. The acrylate allows the covalent bonding to the nanoparticle by a free
radical polymerization. To achieve this, the drug is dissolved in compatible acrylate monomers,
then a surfactant is added along with water, resulting in the formation of micelles. The size of the
micelles is dependent on hydrophobic and hydrophilic interactions in the emulsion. The radical
initiator is then added to cause free radical polymerization of the acrylate in the emulsified
micelles. This results in a stable aqueous emulsion, containing nanoparticles of uniform size.
27

O

O

+

Sodium Dodecyl Sulfate
3% w/v

O

O

Potassium Persulfate
0.5% w/v
Styrene
30% v/v

Butyl acrylate
70% v/v

H2O
78oC

Figure (2.5) General scheme for preparing butyl acrylate:styrene polymer emulsions.

The general procedure for the formation of the polyacrylate nanoparticle emulsions is
highlighted in Figure 2.5. A self-regulating oil bath was used to maintain a temperature of 78 C,
the mixture of styrene (300 µl) and butyl acrylate (700 µl) totaling 1 ml was added to a round
bottom flask. The mixture was stirred at 78 C using a 1.25 cm (300 mg) Teflon-coated magnetic
stir bar at 380 rpm on a Corning PC-420D magnetic stirrer. After 30 minutes, 30 mg of sodium
dodecyl sulfate and 2 ml of deionized water were added, and the stirring speed was increased to
500 rpm. Following 30 minutes, 5 mg of potassium persulfate and 2 ml of deionized water were
added and the stirring speed was further increased to 750 rpm. The resulting emulsion was then
decanted into a collection vial after 6 hours.

The resulting emulsions are analyzed using dynamic light scattering to obtain nanoparticle size
and zeta potential. In addition, in vitro studies are carried out for both human cell cytotoxicity
and antibacterial activity.
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2.5 Experimental Procedures and Results

2.5.1 Synthesis of 5-Acryloylamino-2-Hydroxybenzoic Acid

Figure (2.6) One pot synthesis of compound 2.

The main problem with using 5-ASA was that it required a very polar solvent, so a procedure
utilizing water was used to synthesize the N-acryloyl 5-ASA.49 To a round bottom flask, 5-ASA
(306 mg, 2 mmol) and sodium hydroxide (160 mg, 4 mmol) were dissolved in 30 ml deionized
water. It was noted that smaller amounts of water resulted in higher product yields. While
stirring, the mixture was placed in an ice bath to cool to 0°C. After 20 minutes acryloyl chloride
(195 µl, 2.4 mmol) was added dropwise, then the ice bath was removed, and the mixture
continued to stir for one hour at room temperature (Figure 2.6).

In order to extract the N-acryloyl 5-ASA, the mixture was treated with 1M aqueous HCl, to
provide a final solution pH of 1, which resulted in the precipitation of the desired compound 2.
The product was then filtered, and left overnight to dry. The melting point of the product was
obtained using MEL-TEMP II by Laboratory Devices.
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Yielded 340 mg (82.1%) as violet colored solid. Melting point: 180-185°C. (Figure 2.7) 1H
NMR (400 MHz, DMSO-d6) δ 10.07 (s, 1 H), 8.14 (s, 1 H), 7.71 (d, J=8.9, 1 H), 6.89 (d, J=8.9
Hz, 1 H), 6.34 (dd, J=17.2, 2.0 Hz, 1H), 6.19 (dd, J=17.2, 10.0 Hz, 1H), 5.69 (dd, J=10.0, 2.0
Hz, 1 H).

Figure (2.7) Proton NMR assignment for compound 2.

2.5.2 Synthesis of 5-Acetylamino-2-Hydroxybenzoic Acid (Compound 3)
H2N

COOH
OH
Compound 1

Cl

+

H
N

Aqueous NaOH

O

0°C~R.T

Acetyl chloride

COOH

O
OH
Compound 3

Figure (2.8) One pot synthesis of compound 3.

To a round bottom flask, 5-ASA (306 mg, 2 mmol) and sodium hydroxide (160 mg, 4 mmol)
were dissolved in deionized water. While stirring, the mixture was placed in an ice bath to cool
to 0 °C. After 20 minutes, acetyl chloride (170 µl, 2.4 mmol) was added dropwise, then the ice
bath was removed, and the mixture continued to stir for one hour at room temperature (Figure
2.8).
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In order to extract the N-acetyl-5-ASA, the mixture was treated with 1M aqueous HCl, to
provide a final solution pH of 1, which resulted in the precipitation of the desired compound 3.
The resulting product was then filtered, and left overnight to dry. The melting point of the
product was obtained using a MEL-TEMP II apparatus by Laboratory Devices.

Yielded 290 mg (70%) as a white solid. Melting Point: 212-220 °C. (Figure 2.9) 1H NMR (400
MHz, DMSO-d6) δ 9.83 (br s, 1 H), 8.03 (br s, 1 H), 7.59 (br d, J=8.5 Hz, 1 H), 6.85 (br d, J=8.8
Hz, 1 H), 1.96 (s, 3 H).

Figure (2.9) Proton NMR assignment for compound 3.

2.5.3 Emulsion Polymerization Procedure

Figure (2.10) Formation of nanoparticle emulsions using compound 2.
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The polymerization procedure used for 5-ASA is similar to the procedure used in the Turos
laboratory to prepare antibacterial nanoparticles.5 The polymerization procedure used 20 mg of
compound 2 as a standard amount. Nitrogen was used to flush the air out of the reaction system.
Through trial and error, the optimal oil bath temperature was found to be 73°C. Compound 2 was
dissolved in a 1 ml of 7:3 v/v mixture of butyl acrylate and styrene, and stirred for 20 minutes.
Then sodium dodecyl sulfate (12 weight %, 120 mg) was added along with 2 ml of deionized
water, and this mixture was stirred for another 20 minutes. Finally, potassium persulfate (2.5
weight %, 25 mg) was added to the mixture along with 2 ml of deionized water. The mixture was
then stirred for an additional 6 hours (Figure 2.10).

Figure (2.11) Formation of nanoparticle emulsions using compound 3.

Due to difficulty in loading and successfully obtaining a stable nanoparticle emulsion using 3
weight % of sodium dodecyl sulfate, various other surfactants were examined, though none
proved successful in forming a stable nanoparticle emulsion. The surfactants used were anionic
(sodium dodecyl sulfate), cationic (dodecyl trimethylammonium chloride), zwitterionic ( 3-(N,N32

dimethylmyristylammonio)-propanesulfonate), and non-ionic (Triton x100). Figure 2.11 shows a
similar scheme that was used for the encapsulation of compound 3.

2.5.3.1 Nanoparticle Emulsion Data
Table (2.1) Nanoparticle emulsions using 5-ASA derivative.
Monomer

Surfactant
Weight %

Surfactant
Charge

Temp (°C)

Results

Anionic
Anionic
Anionic
Anionic
Anionic
Zwitterionic
Zwitterionic
Zwitterionic
Zwitterionic
Zwitterionic
Zwitterionic
Anionic
Zwitterionic
Non-ionic
Non-ionic
Anionic

Radical
Initiator
Weight %
0.5
1
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5

30 mg Cpd. 2
30 mg Cpd. 2
30 mg Cpd. 2
30 mg Cpd. 2
20 mg Cpd. 2
20 mg Cpd. 2
20 mg Cpd. 2
20 mg Cpd. 2
20 mg Cpd. 2
30 mg Cpd. 2
20 mg 5-ASA
20 mg 5-ASA
20 mg Cpd. 2
20 mg Cpd. 2
20 mg Cpd. 2
20 mg Salicylic
acid
20 mg Cpd. 2
10 mg Cpd. 2
30 mg Cpd. 2
10 mg Cpd. 3
20 mg Cpd. 3
30 mg Cpd. 3

1
3
3
5
10
3
5
7
10
10
12
12
12
12
12
12

90
90
90
90
65
65
70
70
70
70
73
73
73
73
73
73

Clear, No emulsion
Clear, No emulsion
Clear, No emulsion
Clear, No emulsion
Unstable
Unstable
Unstable
Unstable
Destabilized later
Destabilized later
Red
Red
Unstable
Unstable
Unstable
Homogeneous

12
12
12
12
12
12

Anionic
Anionic
Anionic
Anionic
Anionic
Anionic

2.5
2.5
2.5
2.5
2.5
2.5

73
73
73
73
73
73

Homogeneous
Homogeneous
Homogeneous
Homogeneous
Homogeneous
Homogeneous

Table 2.1 contains data from all the polymerizations that were performed, excluding repetitions,
and contaminated samples. The results show that the optimal temperature for forming an
emulsion using these 5-ASA derivatives was 73°C, and required 12% of the anionic surfactant
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(sodium dodecyl sulfate), along with 2.5% of potassium persulfate. The only surfactant that was
able to produce a homogeneous emulsion was the anionic surfactant SDS. The pH of the
emulsion was measured at 2.3. However, a unique emulsion was produced when we attempted to
encapsulate the free 5-ASA. The emulsion turned nearly black (actually very dark red). It is
hypothesized that it was possibly the free aromatic amine that was causing this. Each compound
used in the polymerization was reacted separately with 5-ASA, and the radical initiator seemed
to cause the undesired side reaction (formation of the red color). To test this, we attempted a
polymerization using only salicylic acid which lacks the NH2 moiety, and it produced a
homogeneous mixture. This indicated that the radical initiator and free aromatic amine of 5-ASA
could not be used together.

2.5.4 Purification of Nanoparticle Emulsions

Table (2.2) Dynamic light scattering data for crude vs purified emulsions.
Emulsion (drug, surfactant, radical
initiator)
10 mg Compound 2, 12%, 2.5%
10 mg Compound 2, 12%, 2.5% (purified)
20 mg Compound 2, 12%, 2.5%
20 mg Compound 2, 12%, 2.5% (purified)
30 mg Compound 2, 12%, 2.5%
30 mg Compound 2, 12%, 2.5% (purified)
No Drug, 12%, 2.5%
No Drug, 12%, 2.5% (purified)

Average Diameter

Average Zeta Potential

41 nm ±2.8
15.6 nm ±0.9
56 nm ±3.2
35 nm ±2.5
82 nm ±6.4
75 nm ±5.9
80 nm ±7.0
28 nm ±2.1

-52 mV ± 4.8
-46 mV ± 3.6
-44 mV ± 3.2
-49 mV ± 3.5
-35 mV ± 2.4
-43 mV ± 3.1
-52 mV ± 3.3
-53 mV ± 4.9

The purification procedure for the resulting emulsions involved centrifugation of 1 ml of the
emulsion in a microcentrifuge tube at (16.1k x g) for 30 minutes. A solid pellet formed at the
bottom of the conical tube, the supernatant was removed with a pipette, and placed in a dialysis
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membrane tube (50K dialysis membrane, Spectrum Laboratories Inc.-Spectra/Pro 1,2,3,4,5,6,7
Regenerated cellulose Dialysis Membrane). The supernatant was dialyzed in deionized water
(200 ml) for 8 hours, replacing the water every two hours. After 8 hours the emulsion was
transferred into another microcentrifuge tube, and centrifugated again at (16.1k x g) for another
30 minutes. The supernatant was removed by pipette and transferred into a vial.

Table 2.2 shows the different sizes produced depending on the amount of drug added during
polymerization. There was a noticeable trend that the nanoparticle increased in size as the
amount of drug loading was increased. In addition, it seems that the dialysis process shrank the
nanoparticles to a smaller diameter. The non-drug loaded nanoparticles were larger than those
containing 10 mg of compound 2. This could be due to some hydrophobic interaction that causes
the nanoparticle to form within a tighter micelle. The purified emulsions were found to exhibit
similar cytotoxicity when compared to the non-purified samples. In addition, it was uncertain if
the drug encapsulated model retained the drug loaded within. Thus all biological studies were
carried out using the non-purified emulsions.

2.6 Biological Studies: Cytotoxicity and Antibacterial Activity
To determine if the derivatives of 5-ASA or the nanoparticle emulsions containing the drug had
any change in activity against common bacteria found in the human digestive system, minimum
inhibitory concentration (MIC) values were determined, and compared. In addition, a
cytotoxicity study was performed in order to assess the toxicity of the analogs, the nanoparticles,
and the nanoparticle components towards human cells.
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2.6.1 Antibacterial Testing of 5-ASA Derivatives and Nanoparticle Emulsions
To investigate whether the nanoparticles possess antibiotic capabilities, each crude emulsion was
tested against methicillin-resistant Staphylococcus aureus (MRSA) (ATCC 43300) and
Escherichia coli (K12) using a 96-well plate broth assay to determine the minimum inhibitory
concentration (MIC).

The original stock emulsion was diluted using Trypticase Soy Broth (TSB) solution to an initial
concentration of 2.56 mg/ml of the 5-ASA derivative, then serial diluted with TSB to half the
concentration each time. A volume of 10 µl of each emulsion dilution was added to the next well
in series, resulting in a final concentration run of 128 µg/ml to 0.012 µg/ml. The MIC was done
in triplicates for each bacterium, with penicillin G being used as a positive control and a blank of
deionized water as a negative control.

To prepare the bacteria for culture, all solutions were autoclaved prior to use. The bacteria were
grown overnight at 37oC on an agar plate composed of BBL TSA II Trypticase Soy Agar (TSA)
and BBL Trypticase Soy Broth (TSB) in a 1:2 ratio at 4.4% concentration. A broth solution of
2.4% TSB was inoculated using the bacteria from the agar plates, and was incubated at 37 oC to
reach a 0.5 McFarland standard. The bacteria was then further diluted by a factor of 1000 using a
broth solution of 2.4% TSB, and 190 µl of the diluted bacterial solution was transferred by
micropipette into each well. The inoculated plates were incubated at 37 oC for 16-20 hours and
the resulting plates were observed for growth and MIC values recorded. The MIC was the lowest
concentration of the antibiotic that completely inhibited bacterial growth (visually) within that
series of dilutions.
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2.6.1.1 Antibacterial Activity Results

Figure (2.12) MIC values for compounds tested against E.coli and MRSA.

Figure 2.12 shows the MIC values for the different compounds that are used in making the
nanoparticle, and 5-ASA and two analogs. It is interesting to see that all the components are not
that effective against MRSA or E.coli including the empty nanoparticle. However, when the
nanoparticle contains compound 2 or compound 3, there was a significant increase in the activity
against MRSA. Compound 2 and compound 3 (without nanoparticle loading) are active against
E.coli, with MIC’s of 32 mg/ml, respectively, but not active against MRSA.

2.6.2 Eukaryotic Cell Model for Cytotoxicity Testing
Human colon cells (HT-29) were recovered from storage in liquid nitrogen. For the initial
recovery the cells were thawed quickly, and then suspended in McCoy’s growth medium made
with 10% fetal bovine serum and 1% gentamycin (antibiotic). Once suspended, the cells were
placed into a cell culture flask, and incubated under an atmosphere of 5% CO 2. The medium was
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changed approximately every two days, and the cells were grown to confluence in about 4-5
days. The cells were sub-cultured (a small amount of the cell were placed into a new flask to
grow) when the cells reached 80% confluence in the original culture flask. The flask was taken
out of the incubator, the medium was drawn off and discarded, the cells were rinsed with 1X
dulbecoo’s phosphate buffer solution (DPBS) (2-3 ml), and then trypsin was administered to
cells in order to detach them from the flask wall. The cells were then suspended in the growth
medium, and one third of the solution was placed into a new flask. The cells were sub-cultured at
a 1:3 ratio from the original amount. Cell counting was performed to determine the number of
cells present in the flask in order to determine the number of cells needed for the testing. The
cells were counted using a hemocytometer glass slide, by adding 50 µl of the cell solution into
100 µl of DPBS and 50 µl of trypan (blue dye), thus giving a dilution of 4x. Cells were counted
on the grid and the cell count was calculated based on dilution and number of blocks counted,
with each block on the grid representing a volume of 0.1 µl.

HT-29 cells were placed into each well of a 96-well plate for preparing the in vitro cytotoxicity
assay. 10,000 cells in 150 µl volume of medium were placed into each well, and incubated
overnight in the CO2 incubator. Triplicate testing was setup for each compound or emulsion with
up to 6 serial dilutions for each drug. The samples were first diluted in the medium in a sterile
test tube, and then serial diluted halving the concentration each time. 50 µl of each concentration
was added to the 150 µl of cells, thus diluting each well an additional 4x.

A blank was also placed on the plate containing only the growth medium, and another control
was setup containing cells and the growth medium. The cells were then incubated for 48 hours.
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After incubation, 20 µl of a 3.75 mg/ml solution of MTT was added into each well, and then
placed back into the incubator for 4 hours. Once removed from the incubator, the medium was
aspirated, and 100 µl of DMSO was added to each well to dissolve the purple crystal. The plates
were shaken for 5 minutes prior to placing them into the plate reader. Results were read at 595
nm, and provided as an absorbance value, which was then calculated into % inhibition by the
formula (control absorption-sample absorption)/control absorption x 100%.

2.6.2.1 Cytotoxicity Assay Results

Figure (2.13) Cytotoxicity of compound 2 and compound 3.
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Cell Inhibition Assay

Figure (2.14) Cytotoxicity of surfactant, sodium dodecyl sulfate.

Figure (2.15) Cytotoxicity assay of compound 2 and compound 3 loaded nanoparticle
emulsions.
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Figures 2.13 displays the cytotoxicity results performed for compound 2, and compound 3 at IC50
of 750 µg/ml, and the corresponding nanoparticle emulsions. It is evident that 5-ASA derivatives
exhibit low cytotoxicity to the cells. Figure 2.14 shows that the surfactant however is extremely
toxic with an IC50 of 20 µg/ml, which is probably due to destabilization of the cell membrane.
Likewise, as Figure 2.15 indicates, all of the nanoparticle emulsions are toxic at an IC 50 of 25
µg/ml. As a result, both drug loaded nanoparticles exhibited high levels of cytotoxicity, deeming
the emulsions unusable for anti-inflammation models.

2.7 Possible Model for Testing Inflammation (Future Studies)
As a result of the observed cytotoxicity, we were unable to carry out the anti-inflammatory
nanoparticle emulsions further for biological applications. However, they would remain viable if
other surfactants or other polyacrylate based nanoparticle emulsions are able to load 5-ASA
derivatives without appreciable cytotoxicity. Then using the activation of PPAR- we could test
for the effectiveness of 5-ASA and its derivatives. This could be done with HT-29 cells
transiently transfected using the Effectene transfection reagent (QIAGEN). To test PPARactivation, we could perform transfections with 500 ng of a minimal promoter construct
containing two copies of PPRE obtained from the cytochrome p450 4A (2XCYP). The renilla
luciferase plasmid (0.1 µg/well) would also be transfected as an internal control for monitoring
transfection efficiency and for normalizing the firefly luciferase activity. Transfected cells would
be incubated for 48 hours at 37°C. Stimulations would be performed for 6 hours with 5-ASA (30
mM). Total cell extracts would be prepared using the Passive Lysis Buffer (Promega). Luciferase
activity would be assayed using Promega's Dual Luciferase assay system.
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2.8 Scanning Electron Microscope Imaging of Nanoparticle Emulsions
HT-29 cells were grown on coverslips for this experiment. A specially coated thermonax
coverslip was placed into each well of a 24 well plate. The cells were grown in each well using a
similar procedure to the cytotoxicity procedure described previously. The nanoparticle emulsion
was then administered 24 hours prior to the affixation procedure (dehydration of cells onto the
coverslip). The plate was then removed from the incubator and the medium was aspirated. Care
was taken to ensure that the cells remained on the coverslip in the wells.

The cells must be dehydrated and affixed for SEM analysis. A solution of 2%
paraformaldehyde/2% glutaraldehyde in 0.1 M phosphate buffer was added to each well and left
for at least 1 hour. Then the sample was rinsed several times with PBS for 15 minutes, followed
by addition of 1% osmium tetroxide in 0.1 M phosphate buffer for 1 hour. Another rinse was
done for 15 minutes with PBS, followed by dehydration using ethanol solutions (70% for 15
minutes, 95% for 15 minutes, 3 changes of 100% for 10 minutes each), followed by 2:1
ethanol/hexamethyldisilazane (HMDS) for 20 minutes, and then 1:2 ethanol/HMDS for 20
minutes, followed by two changes of 100% HMDS for 15 minutes each.

The sample was left in the hood to air dry overnight. The cover slip was then removed and
mounted on the base, and sputter coated with gold-palladium for scanning electron microscopic
imaging.
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2.8.3 Scanning Electron Microscope (SEM) Imaging

Figure (2.16) Scanning electron microscope image of HT-29 cells.

Figure (2.17) Scanning electron microscope image of nanoparticle emulsion (compound 2
loaded).
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Figure (2.18) Scanning electron microscope image of HT-29 cells treated with nanoparticle
emulsions (compound 2 loaded).
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Figure 2.16 shows the HT-29 cells look confluent and healthy. In Figure 2.17 the SEM image
shows a clustering of nanoparticles. No image could be formed where the nanoparticles were not
clustered or separated from each other. This was most likely due to the dehydration process
causing the nanoparticles to form clusters.

Figure 2.18 shows that the cells after 24 hours of nanoparticle administration, and the cells were
beginning to detach and become round. There seems to be a lot of cell components and other
micelles in the background. The images provide an example of the nanoparticle emulsion
causing inhibited cell growth. It is somewhat hard to see a clear image differentiating between
the cell and the nanoparticle. So attemps to find an image where the nanoparticle was interacting
with the human cell were not successful.

2.10 Future Studies
What was learned from these experiments with 5-ASA and its derivatives was that the
poly(styrene-butyl acrylate) nanoparticle emulsions have a limitation in loading these particular
bioactive compounds. As such an increased amount of surfactant is required in order to stabilize
the micelles sufficiently to form stable polyacrylate polymers that can load the bioactive
compound. However, the increase in surfactant quantities also increases the cytotoxicity towards
human cells and as a result deem some bioactive compounds unusable as drug-loaded
nanoparticle emulsions. Though previous research demonstrated that purification methods postemulsification help reduce the cytotoxicity, in this case the cytotoxic levels of the nanoparticle
emulsions were too great to observe any useful reduction in cytotoxicity.

45

Additional work may be done to find alternate polyacrylate emulsion models that allow for an
increase in loading of 5-ASA analogs, and more importantly, reduce cytotoxicity of the
nanoparticle emulsion. This would permit in vitro testing against anaerobic bacteria, and
eukaryotic cell inflammation models. In chapter 3, studies on a new homo(menthyl acrylate)
polymer nanoparticle emulsion are presented, that provide an increase in loading of compounds,
while greatly reducing cytotoxicity.
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CHAPTER THREE

POLYACRYLATE NANOPARTICLE EMULSIONS: USE OF MENTHYL ACRYLATE
MONOMERS TO FORM CHIRAL DRUG LOADING HOMOPOLYMER NANOPARTICLE
EMULSIONS

3.1 Introduction
To further advance our laboratory’s work on polyacrylate nanoparticle emulsions, the next
objective was to test the possibility of replacing one of the monomers in order to introduce a
chiral component to the polyacrylate nanoparticle framework. With polyacrylate nanoparticle
emulsions consisting of butyl acrylate/styrene or methyl methacrylate/styrene mixtures, it was
most feasible to replace the acrylate ester monomer in order to easily introduce a chiral
component to the polyacrylate. There were no commercially available enantiopure chiral acrylate
esters that would be cost effective and readily available in large quantities. Thus, menthol was
chosen as a cheap chiral alcohol that could be converted into the acrylate ester. Both the
naturally occurring L-menthol and the enantiomer D-menthol in Figure 3.1 are available
commercially.
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OH
R
R

S

(-)-L-Menthol

Figure (3.1) Structures of L-menthol and D-menthol.

3.2 Synthesis of Menthyl Acrylate
The menthol alcohol was converted to the acrylate ester via the addition of acryloyl chloride in
the presence of a base. The first goal was to try to replace the butyl acrylate monomer with the
menthyl acrylate monomer to prepare polyacrylate nanoparticle emulsions having a ratio of 7:3
of the acrylate ester monomer:styrene monomer. In addition, experiments were done to alter this
initial ratio to determine the optimal combination of monomers needed to form stable
polyacrylate nanoparticle emulsions.
O
OH

O
Triethylamine

O
+
Cl
L-Menthol

Ethyl acetate
0ºC-R.T.
24hr

Acryloyl chloride

Compound 4

L-Menthyl acrylate
Compound 5

Figure (3.2) Scheme for the synthesis of L-menthyl acrylate (L-MtA).
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O
+
Cl
D-Menthol

Ethyl acetate
0ºC-R.T.
24hr

Acryloyl chloride

Compound 6

D-Menthyl acrylate
Compound 7

Figure (3.3) Scheme for the synthesis of D-menthyl acrylate (D-MtA).

Figure 3.2 and Figure 3.3 show the synthetic scheme for L-menthyl acrylate and D-menthyl
acrylate, respectively, and follow as such: To a round bottom flask was added 250 ml of ethyl
acetate, then 5.0 g (3.2 mmol) of the desired antipode of menthol and 8.9 ml (6.4 mmol) of
trimethylamine were introduced. The mixture was left stirring at 0 oC for 1 hour then 3.1 ml (3.8
mmol) of acryloyl chloride was added dropwise. The ice bath was removed and the reaction was
left stirring overnight.

The workup of the reaction was performed by washing once with 100 ml of deionized water,
three times with 80 ml of saturated ammonium chloride solution, three times with 80 ml of
saturated sodium bicarbonate solution, and once with brine. The organic layers was then dried
with anhydrous sodium sulfate. The ethyl acetate was evaporated, and the resulting crude
product was purified via flash column chromatography using hexane as the solvent. Hexane was
evaporated, and the resulting product was obtained.
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L-menthyl acrylate (L-MtA): Yielded 4.6 ml (4.8 g, 72%) as a clear liquid.
[𝛼] = -83.1; 1H NMR (400 MHz, CDCl3) δ 6.37 (dd, J=17.3, 1.3 Hz, 1 H), 6.09 (dd, J=17.3,
10.4 Hz, 1 H), 5.78 (dd, J=10.4, 1.3 Hz, 1 H), 4.75 (td, J=10.9, 4.4 Hz, 1 H), 2.00 (m, 1 H), 1.86
(m, 1 H), 1.69 (br d, J=2.6 Hz, 1 H), 1.66 (m, 1 H), 1.49 (m, 1 H), 1.40 (m, 1 H), 1.06 (m, 1 H),
0.99 (m, 1 H), 0.89 (m, 1 H), 0.89 (d, J=6.9 Hz, 6 H), 0.76 (d, J=6.9 Hz, 3 H).

D-menthyl acrylate (D-MtA): Yielded 4.9 ml (5.1 g, 76%) as a clear liquid.
[𝛼] = +83.0; 1H NMR (400 MHz, CDCl3) δ 6.36 (dd, J=17.3, 1.4 Hz, 1 H), 6.09 (dd, J=17.3,
10.4 Hz, 1 H), 5.77 (dd, J=10.4, 1.4 Hz, 1 H), 4.74 (td, J=10.9, 4.4 Hz, 1 H), 2.00 (m, 1 H), 1.85
(m, 1 H), 1.68 (br d, J=2.7 Hz, 1 H), 1.64 (m, 1 H), 1.48 (m, 1 H), 1.39 (m, 1 H), 1.05 (m, 1 H),
0.98 (m, 1 H), 0.89 (m, 1 H), 0.87 (d, J=6.9 Hz, 6 H), 0.74 (d, J=6.9 Hz, 3 H).

3.3 Preparation of Polyacrylate Nanoparticle Emulsion Using Menthyl Acrylate and
Styrene

Figure (3.4) Scheme for the formation of polyacrylate nanoparticle emulsion using L-menthyl
acrylate and styrene as monomers.
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Figure (3.5) Scheme for the formation of polyacrylate nanoparticle emulsion using D-menthyl
acrylate and styrene as monomers.

The general procedure for the formation of the polyacrylate nanoparticle emulsions is
highlighted in Figure 3.4 and Figure 3.5. This procedure was very similar to previous protocols
that were developed for other acrylate ester and styrene monomer combinations within our lab. A
self-regulating oil bath was used to maintain a temperature of 78°C, the mixture of styrene and
menthyl acrylate totaling 1 ml were added to a round bottom flask. The mixture was stirred using
a 1.25 cm (300 mg) Teflon-coated magnetic stir bar at 380 rpm on a Corning PC-420D magnetic
stirrer. After 30 minutes, 30 mg of sodium dodecyl sulfate and 2 ml of deionized water were
added, and the stirring speed was increased to 500 rpm. Following 30 minutes, 5 mg of
potassium persulfate and 2 ml of deionized water were added and the stirring speed was
increased to 750 rpm. The resulting emulsion was then decanted into a collection vial after 6
hours.

The newly formed nanoparticle emulsions contain a chiral component (menthol) attached to the
polyacrylate chain. The backbone of the polyacrylate nanoparticle presumably remains racemic
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due to the radical mechanism of its formation. Various dilutions were carried out to investigate
the effect of monomer ratios on stability and physical properties of the resulting nanoparticle
emulsions.

3.4 Dynamic Light Scattering Analysis of Size and Zeta Potential of Emulsions
Dynamic light scattering measurements were used to determine the size of the nanoparticles
within the emulsions. The average size and surface charge of the emulsion was analyzed using a
Malvern Zetasizer nano-ZS instrument. To prepare the samples for the analyses, the freshlyprepared emulsion was subjected to centrifugation at 10,000 rpm for 5 minutes using an
Eppendorf Centrifuge 5424. An aliquot of the liquid emulsion was then drawn and deposited into
a Malvern disposable folded capillary cell DTS-1070. Each sample was analyzed in triplicate,
and each data collection consisted of 1 run of 20 scans (for size analysis) and 3 runs of 100 scans
(for zeta potential determination).

3.4.1 Size and Zeta Potential Results Using Dynamic Light Scattering Instrument

Table (3.1) Size and zeta potential for emulsions using L-menthyl acrylate and styrene.
Sample

Average Size (nm)

Average Zeta Potential (-mV)

L-MtA 10%

73.9 ± 4.3

56 ± 2.9

L-MtA 20%

69.0 ± 3.9

53 ± 2.6

L-MtA 30%

62.2 ± 3.3

60 ± 4.0

L-MtA 40%

99.0 ± 6.2

56 ± 4.1

L-MtA 50%

60.4 ± 5.3

56 ± 2.3

L-MtA 60%

56.2 ± 5.1

53 ± 3.6
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Table (3.1) (Continued)
L-MtA 70%

58.2 ± 3.2

61 ± 3.8

L-MtA 80%

52.8 ± 3.0

45 ± 3.3

L-MtA 90%

82.4 ± 2.9

59 ± 3.0

L-MtA 100%

79.9 ± 4.2

56 ± 2.8

Table (3.2) Size and zeta potential for emulsions using D-menthyl acrylate and styrene.
Sample

Average Size (nm)

Average Zeta Potential (-mV)

D-MtA 10%

63.5 ± 4.1

47 ± 4.5

D-MtA 20%

58.0 ± 3.8

47 ± 4.2

D-MtA 30%

60.8 ± 3.7

45 ± 4.1

D-MtA 40%

54.3 ± 1.5

50 ± 4.0

D-MtA 50%

54.3 ± 2.2

48 ± 3.9

D-MtA 60%

58.4 ± 3.1

50 ± 3.3

D-MtA 70%

53.9 ± 2.2

45 ± 4.5

D-MtA 80%

57.3 ± 2.7

49 ± 4.1

D-MtA 90%

54.0 ± 2.9

41 ± 3.8

D-MtA 100%

58.4 ± 3.1

51 ± 3.9

Table (3.3) Size and zeta potential for emulsions using racemic menthyl acrylate and styrene.
Sample

Average Size (nm)

Average Zeta Potential (-mV)

Rac-MtA 10%

60.4 ± 3.2

52 ± 3.3

Rac -MtA 20%

60.6 ± 3.6

50 ± 5.4

Rac -MtA 30%

59.3 ± 1.5

47 ± 4.8

Rac -MtA 40%

64.1 ± 2.2

51 ± 4.3

Rac -MtA 50%

66.1 ± 2.3

41 ± 4.2

Rac -MtA 60%

51.6 ± 3.1

34 ± 2.6

Rac -MtA 70%

63.3 ± 2.8

43 ± 3.5
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Table (3.3) (Continued)
Rac -MtA 80%

70.2 ± 2.4

42 ± 3.1

Rac -MtA 90%

55.6 ± 2.3

53 ± 2.8

Rac -MtA 100%

57.8 ± 2.1

46 ± 3.9

Table 3.1-3.3 display the average size of the nanoparticles contained within the final emulsions.
Table 3.1 is for emulsions formed from of L-menthyl acrylate and styrene with the percentage
shown is related to the amount of L-menthyl acrylate within the organic component of the
emulsion. For example, L-MtA 20% represents 20% L-menthyl acrylate and 80% styrene by
weight composition of the total organic components. Table 3.2 is for emulsions formed via the
use of D-menthyl acrylate. Table 3.3 is for emulsions formed using a 50/50 mixture of Lmenthyl acrylate and D-menthyl acrylate.

Surprisingly, all combinations formed very stable emulsions as determined by the zeta potential
values all being larger than -30 mV. In addition, all polyacrylate particles measured within the
35-67 nm range, with no specific trend. As a result, it was possible to form a stable nanoparticle
emulsion using any mixture of menthyl acrylate and styrene as co-monomers up to 20% total
weight of the aqueous emulsion (80% of the weight being water).

3.5 Optical Rotation of Menthyl Acrylate and Styrene Based Nanoparticle Emulsions
Using enantiopure menthol alcohols, we were able to produce enantiopure forms of the menthyl
acrylates and incorporate them into the polyacrylate backbone of the nanoparticle emulsions. In
order to observe if these new chiral polymer had any unique optical properties we analyzed their
optical activity using an AUTOPOL IV automatic polarimeter made by Rudolph Research
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Analytical. In order to obtain this data, all samples were diluted by a factor of 1:200 in deionized
water and measured at 20°C.

3.5.1 Optical Activity Results of Menthyl Acrylate and Styrene Based Nanoparticle
Emulsions

Table (3.4) Optical rotation vs menthyl acrylate values for menthyl acrylate/styrene nanoparticle
emulsions.
Sample

Optical

Sample

Rotation

Optical

Sample

Rotation

[𝛼]

Optical
Rotation

[𝛼]

[𝛼]

D-MtA 10%

+1.8

Rac-MtA 10%

0.0

L-MtA 10%

-1.8

D-MtA 20%

+2.0

Rac -MtA 20%

0.0

L-MtA 20%

-2.0

D-MtA 30%

+2.8

Rac -MtA 30%

0.0

L-MtA 30%

-2.6

D-MtA 40%

+3.8

Rac -MtA 40%

0.0

L-MtA 40%

-3.8

D-MtA 50%

+6.2

Rac -MtA 50%

0.0

L-MtA 50%

-6.0

D-MtA 60%

+7.8

Rac -MtA 60%

0.0

L-MtA 60%

-8.0

D-MtA 70%

+8.4

Rac -MtA 70%

0.0

L-MtA 70%

-8.4

D-MtA 80%

+8.8

Rac -MtA 80%

0.0

L-MtA 80%

-8.8

D-MtA 90%

+9.6

Rac -MtA 90%

0.0

L-MtA 90%

-9.8

D-MtA 100%

+10.8

Rac -MtA 100%

0.0

L-MtA 100%

-11.0
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In order to better determine if any trend exists within the optical activity results, the data in Table
3.4 was converted to the graph in Figure 3.6. Both enantiomeric forms of the acrylate ester in the
menthyl acrylate/styrene polyacrylate nanoparticles follow a similar pattern. Though the overall
sinusoidal pattern is yet to be understood, it does seem that there is a consistency, and that the
optical activity increased as the concentration of menthyl acrylate was also increased.

Optical Rotation of MtA-St Nanoparticles
Optical Rotation (α)
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6

D-MtA

4

L-MtA

2
0
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20%

30%

40%

50%

60%

70%

80%

90%

100%

Concentration of MtA (%)

Figure (3.6) Optical rotation vs for menthyl acrylate/styrene nanoparticle emulsions.

3.6 Discussion of Menthyl Acrylate and Styrene Based Polyacrylate Nanoparticles
Experiments to prepare stable emulsions of menthyl acrylate containing nanoparticles were
successful. Most surprisingly was the ability to form stable nanoparticle emulsions using only the
menthyl acrylate as the monomer. This provided the first case of being able to form a homo
polymer using the nanoparticle emulsion technique researched in our laboratory. By eliminating
the need for the co-monomer, and the ability to use chiral menthyl acrylate monomers to
constitute 100% of the polymer within the nanoparticle framework, highly chiral environments
56

could be created within the emulsion. The next goal was to investigate if the menthyl acrylate
emulsions could produce similar drug delivery properties compared to those observed in the
butyl acrylate/styrene polyacrylate systems.

3.7 Studies on the Preparation and Properties of Poly(Menthyl Acrylate) Nanoparticles
The drug loading capabilities of the menthol-based nanoparticles was investigated using
penicillin G as a test antibiotic. A central question was whether these new nanoparticles would
allow for an increase in loading of the bioactive compound (in this case penicillin G). Previous
nanoparticle emulsion typically allowed for a 3% loading of antibiotic by weight of the organic
component of the emulsion, resulting in a maximum final concentration of 0.6% of the bioactive
compound.

Aqueous Phase
Polyacrylate
Antibiotic
Surfactant
Enzyme

Organic Phase

Figure (3.7) The emulsified polyacrylate nanoparticle protecting the loaded antibiotic against
degradative enzymes.

A second question was if the newly formed polyacrylate nanoparticle emulsion would show
antibacterial activity against Staphylococcus aureus (SA) (ATCC 25923) and Methicillin57

resistant Staphylococcus aureus (MRSA) (ATCC 43300). This would confirm that the
nanoparticle emulsion is able to carry and protect penicillin G from enzymatic degradation by
penicillinase, while being able to release the drug to inhibit the growth of the bacteria as depicted
in Figure 3.7.

3.7.1 Encapsulation of Penicillin G into Poly(Menthyl Acrylate) Nanoparticle Emulsion

Figure (3.8) Encapsulation of penicillin G into the poly(menthyl acrylate) nanoparticle
emulsions.

The general procedure for the encapsulation of penicillin G into the poly(menthyl acrylate)
nanoparticle emulsions is highlighted in Figure 3.8. A self-regulating oil bath was used to
maintain a temperature of 78 °C, menthyl acrylate (L or D) totaling 1 ml was added to a round
bottom flask. In order to keep the polymer composition similar for all drug loading
encapsulation, penicillin G was added as an additional % component and was not compensated
by reduction of monomer or surfactant. Penicillin G was added at concentrations of +1% to
+20%. The mixture was stirred using a 1.25 cm (300 mg) Teflon-coated magnetic stir bar at 380
rpm on a Corning PC-420D magnetic stirrer. After 30 minutes, 30 mg of sodium dodecyl sulfate
and 2 ml of deionized water were added, and the stirring speed was increased to 500 rpm. After
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30 minutes, 5 mg of potassium persulfate and 2 ml of deionized water were added and the
stirring speed was increased to 750 rpm. The resulting emulsion was then decanted into a
collection vial after 6 hours.

3.7.1.1 Dynamic Light Scattering Analysis of Size and Zeta Potential of Emulsions
Dynamic light scattering measurements were used to determine the size of the nanoparticles
within the emulsions. The average size and surface charge of the emulsion was analyzed using a
Malvern Zetasizer nano-ZS instrument. To prepare the samples for the analyses, the freshlyprepared emulsion was subjected to centrifugation at 10,000 rpm for 5 min using an Eppendorf
Centrifuge 5424. An aliquot of the liquid emulsion was then drawn and deposited into a Malvern
disposable folded capillary cell DTS-1070. Each sample was analyzed in triplicate, and each data
collection consisted of 1 run of 20 scans (for size analysis) and 3 runs of 100 scans (for zeta
potential determination).

Average Size of Nanoparticle Emulsion
Average Size in (nm)
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1% 2% 3% 4% 5% 6% 7% 8% 9% 10% 11% 12% 13% 14% 15% 16% 17% 18% 19% 20%

% Pen G
Pen G D-MtA

Pen G L-MtA

Figure (3.9) Average size of nanoparticle emulsions with increasing penicillin G loading of both
L-menthyl acrylate polymers and D-menthyl acrylate polymers.
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Average Zeta Potential of Nanoparticle Emulsions
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Figure (3.10) Average zeta potential for nanoparticle emulsions with increasing penicillin G
loading of both L-menthyl acrylate polymers and D-menthyl acrylate polymers.

Figure 3.9 shows that both (L-menthyl acrylate and D-menthyl acrylate) homopolymer
nanoparticle systems were able to achieve a significantly higher drug loading compared to the
copolymer system of butyl acrylate/styrene. The poly(menthyl acrylate) emulsions can contain
up to 20% penicillin G (by weight of organics), compared to only 3% for the previous butyl
acrylate/styrene systems. The increased loading capability is likely indicative of additional
stability within the matrix of the nanoparticles, which would deserve further exploration.
Figure 3.10 confirms the stabilities of both L-menthyl acrylate and D-menthyl acrylate polymer
nanoparticle emulsions while encapsulating penicillin G, with zeta potential values above -30
mV.
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3.7.2 In vitro Antibacterial Testing of Poly(Menthyl Acrylate) Nanoparticle Emulsions
To investigate whether the nanoparticles possess antibiotic capabilities, each crude emulsion was
tested against Staphylococcus aureus (SA) (ATCC 25923) and methicillin-resistant
Staphylococcus aureus (MRSA) (ATCC 43300) using a 96-well plate broth assay to determine
the minimum inhibitory concentration (MIC).

The original stock emulsion was diluted using Trypticase Soy Broth (TBS) solution to an initial
concentration of 1.28 mg/ml of the penicillin G within the emulsion, then serial diluted with TSB
to half the concentration each time. A volume of 10 µl of each emulsion dilution was added to a
well in series, resulting in a final concentration run of 64 µg/ml to 0.012 µg/ml. The MIC was
done in triplicates for each bacterium, with penicillin G being used as a positive control and a
blank of water as a negative control.

To prepare the bacteria for culture, all solutions were autoclaved prior to use. The bacteria were
grown overnight at 37oC on an agar plate composed of BBL TSA II Trypticase Soy Agar (TSA)
and BBL Trypticase Soy Broth (TSB) in a 1:2 ratio at 4.4% concentration. A broth solution of
2.4% TSB was inoculated using the bacteria from the agar plates, and was incubated at 37 oC to
reach a 0.5 McFarland standard. The bacteria was then further diluted by a factor of 1000 using a
broth solution of 2.4% TSB, and 190 µl of the diluted bacterial solution was transferred by
micropipette into each well. The inoculated plates were incubated at 37 oC for 16-20 hours and
the resulting plates were observed for growth and MIC values recorded. The MIC was the lowest
concentration of the antibiotic that completely inhibited bacterial growth (visually) within that
series of dilutions. Additionally, in order to confirm that the nanoparticle emulsions are able to
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protect the drug from enzymatic degradation, a Kirby-Bauer assay was performed with the
addition of penicillinase protein (Sigma Aldrich). One plate was tested with the penicillin Gloaded nanoparticle emulsion and penicillin G against S. aureus, while another plate was set up
with the addition of penicillinase (100 µg) into the agar media.

3.7.2.1 In vitro Antibacterial Testing Results
The results obtained from the antibacterial assays demonstrated that the poly(menthyl acrylate)
nanoparticle emulsions do not possess any antibacterial properties without a bioactive compound
loaded into the nanoparticles. In addition, the encapsulated penicillin G nanoparticles had a MIC
value of 32 µg/ml. Though it was lower antibacterial activity compared to the free penicillin G
control, this result was as expected, because previous penicillin G encapsulated nanoparticles
demonstrated a decrease in bioactivity also (Table 3.5).

The most important results of this assay were the MIC values for penicillin G-loaded
poly(menthyl acrylate) nanoparticles when comparing activity against SA vs MRSA. The
penicillin G loaded nanoparticles exhibited the same activity against both non-resistant and
resistant forms of the microbe, with MIC’s of 32 mg/ml. This suggests that the nanoparticle
emulsion protects penicillin from the degradative enzyme (penicillinase) that is produced by
MRSA, or that is added to the culture media. In addition, the Kirby-Bauer test provided a 35 mm
zone of inhibition for penicillin G against S. aureus without penicillinase added and a 1 mm zone
of inhibition in the presence of penicillinase, while the penicillin G-loaded nanoparticles
exhibited a zone of inhibition of 25 mm for both the penicillinase-free plate and that containing
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added penicillinase. This further confirms the ability of the nanoparticle emulsion to protect the
penicillin loaded within the nanoparticles, without reducing its bioactivity.

Table (3.5) MIC values of penicillin G-loaded poly(menthyl acrylate) nanoparticle emulsions.
Sample

MIC for SA

MIC for MRSA

(ATCC 25923)

(ATCC 43300)

No drug D-MtA nanoparticle

>256 µg/ml

>256 µg/ml

No drug L-MtA nanoparticle

>256 µg/ml

>256 µg/ml

Pen G encapsulated D-MtA

32 µg/ml

32 µg/ml

Pen G encapsulated L-MtA

32 µg/ml

32 µg/ml

Pen G

0.25 µg/ml

16 µg/ml

3.8 In vitro Cytotoxicity Studies for Poly(Menthyl Acrylate) Nanoparticle Emulsions
In vitro cell cytotoxicity of the menthyl acrylate nanoparticle emulsion was tested on two human
cell lines, human colorectal carcinoma cells HCT-116 cells, and human embryonic kidney cells
HEK 293. HCT-116 cells were grown in Dulbeco’s Minimum Essential Medium (DMEM) with
10% fetal bovine serum and 0.1% penicillin/streptomycin as complete growth medium for
several days at 37oC under an atmosphere of 5% CO2 to reach confluence. HEK 293 cells were
grown in Eagle Minimum Essential Medium (EMEM) with 10% fetal bovine serum and 0.1%
penicillin/streptomycin as complete growth medium for several days at 37 oC under an
atmosphere of 5% CO2 to reach confluence. Each cell type was then plated onto 96-well plates,
at 50,000 cells per well at a volume of 150 µl with the respective complete growth medium. The
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cells were counted using a hemocytometer and then incubated for 24 hours at 37 oC under an
atmosphere of 5% CO2.

The test emulsion was diluted using the complete growth medium for each cell type, and added
into the wells of each test plate to give a final concentration of penicillin G (loaded within the
nanoparticle emulsions) of 2 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, and 0.0625
mg/ml within a series. The testing was done in triplicate and one well in each triplicate was left
untreated as the negative control for 100% growth.

The plates were further incubated and monitored for 48 hours at 37 oC under an atmosphere of
5% CO2. A 5 mg/ml solution of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide
(MTT) in sterile phosphate-buffered saline (PBS) was added to give a 10% final concentration in
each well. The plates were then further incubated for 4 hours at 37 oC under an atmosphere of 5%
CO2 to allow for the formation of the purple crystals of 1-(4,5-dimethylthiazol)2-yl)-3,5diphenylformazan. The liquid was then aspirated from each well and 100 µl of dimethylsulfoxide
(DMSO) was added to each well, and gently shaken for 1 min to allow for complete dissolution
of the crystals. The IC50 value for the assay was determined using a BioTek Synergy H1 hybrid
plate reader at both 595 nm and 630 nm. The IC 50 was determined as the well with at least 50%
cell viability compared to the untreated control cell with 100% cell growth.
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3.8.1 Cytotoxicity Results
Table (3.6) IC50 assay values for poly(menthyl acrylate) nanoparticle emulsion.
Sample

IC50 for HCT-116

IC50 for HEK-293

No drug D-MtA nanoparticle

>2 mg/ml

>2 mg/ml

No drug L-MtA nanoparticle

>2 mg/ml

>2 mg/ml

Pen G encapsulated D-MtA

>2 mg/ml

>2 mg/ml

Pen G encapsulated L-MtA

>2 mg/ml

>2 mg/ml

The cytotoxicity assay results indicated that both the penicillin G loaded nanoparticle and the
non-drug loaded nanoparticle had very low cytotoxicity against both cancerous and noncancerous human cell lines. Results in Table 3.6 demonstrated that the new homopolymer
nanoparticle emulsions would be viable for drug delivery as it may be relatively safe to
administer in therapeutic doses.

3.9 Imaging the Poly(Menthyl Acrylate) Nanoparticle Emulsion Using Scanning Electron
Microscope (SEM)
A sample of poly(menthyl acryloyl) nanoparticle emulsion was prepared for imaging using
scanning electron microscopy. The samples were initially prepared by lyophilization of the
emulsion, which resulted in a dry powder that could be added to the sample holder for the
scanning electron microscope instrument. The samples were placed onto an aluminum-coated
sample holding tape, mounted onto a copper tape, placed onto the scanning electron microscope
sample holder. The initial resulting image was very difficult to discern and it was most likely due
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to the non-conductive nature of the material, causing the electrons to build up on the surface of
the material that distorted in the resulting image.

To try to resolve the issue, the sample was diluted 400X with deionized H 2O and a drop of the
diluted emulsion was placed on the conductive aluminum coated sample holding tape. The
sample was placed in the -80°C freeze for a few hours, then immediately lyophilized to dry the
sample directly onto the sample holding tape to produce an even distribution of the material. In
addition, the sample containing tape was sputter-coated with gold-palladium coating in order to
increase the conductivity of the resulting sample, thus preventing or reducing the accumulation
of electrons on the surface of the sample, and thus reducing distortions.

Figure (3.11) Scanning electron microscope image of a cluster of nanoparticle spheres.

Figure 3.11 demonstrated that the clumping of nanoparticles occurs due to the dehydration
process of the sample preparation, producing an individual sphere within the emulsion. The
imaged trails appear to be artifacts of the drying process as the nanoparticles clustered.
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Figure (3.12) Scanning electron microscope image of an isolated nanoparticle sphere.

Poly(menthyl acrylate) nanoparticles exhibited a greater insulating property than previous
polyacrylate nanoparticles, and as a result they are rather difficult to image at high resolution.
The samples were prepared on an aluminum-coated surface, and the samples were coated with a
layer of palladium-gold to allow for better resolution. The images remained distorted, and thus
the exact size determination of individual spheres was not possible (Figure 3.12).

Small improvements in the resulting images were observed when the sample was more dilute,
and when the sample was directly prepared onto the samples holder rather than separately
lyophilizing the sample, then loading onto the SEM sample holder. In addition, increasing the
exposure time of the sample to palladium-gold plating may increase the conductivity of the
sample to provide a better image.
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3.10 5-ASA Derivatives Revisited
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Compound 2 covalently bound to
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Figure (3.13) Preparation of covalently-bound compound 2 poly(L-menthyl acrylate)
nanoparticle emulsions.
O
O

Sodium dodecyl sulfate
3% w/v

O
O

O
HN

L-menthyl acrylate
Potassium persulfate
0.5% w/v
H
N

COOH

HOOC

H2O

O

OH

Compound 3 encapsulated in
poly(L-menthyl acrylate) nanoparticle emulsion

78oC
OH
Compound 3

Figure (3.14) Preparation of encapsulated compound 3 poly(L-menthyl acrylate) nanoparticle
emulsions.
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5-ASA derivatives that were synthesized in chapter 2 were revisited in the hope of loading them
into a nanoparticle emulsion with decreased cytotoxicity. Having observed the increase in drug
loading capacity of the poly(menthyl acrylate) nanoparticle emulsions along with a decrease in
cell cytotoxicity provided a new hopeful procedure for loading 5-ASA derivatives while
reducing the cell cytotoxicity, which was one of the key issues preventing the application of 5ASA loaded nanoparticle emulsions. Preliminary results were obtained by using a procedure for
loading penicillin G into poly(menthyl acrylate) nanoparticles.

The general procedure for the loading of 5-ASA derivative into the poly(menthyl acrylate)
nanoparticle emulsions is highlighted in Figure 3.13 for N-acryloyl-5-aminosalicylic acid and
Figure 3.14 for N-acetyl-5-aminosalicylic acid. A self-regulating oil bath was used to maintain a
temperature of 78°C, 1ml of L-menthyl acrylate totaling 1 ml was added to a round bottom flask.
In order to keep the polymer composition similar for all drug loading encapsulation, penicillin G
was added as an additional % component and was not compensated by reduction of monomer or
surfactant. Each 5-ASA derivative was added at 3% by weight (30 mg). The mixture was stirred
using a 1.25 cm (300 mg) Teflon-coated magnetic stir bar at 380 rpm on a Corning PC-420D
magnetic stirrer. After 30 minutes, 30 mg of sodium dodecyl sulfate and 2 ml of deionized water
were added, and the stirring speed was increased to 500 rpm. After 30 minutes, 5 mg of
potassium persulfate and 2 ml of deionized water were added and the stirring speed was
increased to 750 rpm. The resulting emulsion was then decanted into a collection vial after 6
hours.
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The covalently-bound N-acryloyl-5-ASA in poly(L-menthyl acrylate) nanoparticles measured an
average diameter of 49 (± 1.9) nm and had a zeta potential of -55 (± 5.1) mV. The encapsulated
N-acetyl-5-ASA in poly(L-menthyl acrylate) nanoparticles measured an average diameter of 72
(± 1.7) nm and had a zeta potential of -47 (± 3.6) mV.

Antibacterial testing was performed using the same method as previously reported in Section
2.6.1. The antibacterial results obtained were similar to those previously reported with 5-ASA
derivatives loaded into poly(styrene-butyl acrylate) nanoparticle emulsions against methicillinresistant Staphylococcus aureus (MRSA) (ATCC 43300) and Escherichia coli (K12). Emulsions
of covalently-bound N-acryloyl-5-ASA poly(L-menthyl acrylate) nanoparticles showed an MIC
value of 8 µg/ml against MRSA and 128 µg/ml against E. coli. Emulsions of poly(L-menthyl
acrylate) nanoparticle containing encapsulated N-acetyl-5-ASA showed an MIC value of 32
µg/ml against MRSA and 128 µg/ml against E. coli.

Cell cytotoxicity studies were carried out as previously reported in Section 2.6.2 with HT-29
cells. The resulting IC50 values for both N-acryloyl-5-ASA and N-acetyl-5-ASA loaded into the
poly(L-menthyl acrylate) nanoparticle emulsions were vastly improved (IC 50 of 500 µg/ml)
compared to the previously reported IC50 of 20 µg/ml for the corresponding poly(styrene-butyl
acrylate) nanoparticle emulsions.

This provides renewed interest in the application of bioactive compounds that were previously
problematic to load into poly(styrene-butyl acrylate) nanoparticle emulsions. Though additional
experiments are required to find the potential loading capability of 5-ASA derivatives into
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poly(menthyl acrylate) nanoparticle emulsions, the preliminary results obtained in this present
study provide opportunities for expansion to various other classes of bioactive compounds.

3.11 Discussion
We have observed that the substitution of the butyl acrylate monomer for the menthyl acrylate
monomer allows for the construction of chiral polyacrylate nanoparticle emulsions. The use of
the menthyl acrylate monomer provided the first example of forming a homopolymer
nanoparticle emulsion using the polymerization emulsion technique. In addition, by synthesizing
menthyl acrylate as the monomer we were able to produce enantiomerically pure nanoparticles
from enantiomerically pure L-menthol and D-menthol.
The emulsions have superior drug-loading properties to those of previous polyacrylate
nanoparticle emulsions. There appear to be no sizable distinctions between the all-D and all-L
menthyl acrylate nanoparticles, in either their shape, diameters, surface charge, drug loading
capabilities, or bioactivities. The improved antibacterial activity of the penicillin-encapsulated
poly(menthyl acrylate) nanoparticle emulsions are due to their ability to encapsulate nearly 700%
more bioactive compound compared to our previous butyl acrylate/styrene system, while
maintaining a highly uniform and stable emulsion.

In the next and final chapter of this dissertation the possibility of removing all non-bioactive
monomers from nanoparticle construction was explored. Avoiding the use of co-monomers
during the emulsion polymerization procedure allows for greater amount of loading of the
bioactive antibacterial monomer, producing a homopolymer nanoparticle emulsion composed
solely of the antibiotic monomer.
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CHAPTER FOUR

POLYACRYLATE NANOPARTICLE EMULSIONS: FORMING HOMO POLY (NACRYLOYLCIPROFLOXACIN) AS AN ANTIBACTERIAL POLYMER EMULSION

4.1 Introduction
As a continuation to the mixed ciprofloxacin polyacrylate nanoparticle emulsions described in
chapter three, this chapter delves into tackling the issue of limited loading of bioactive
compounds, and the need for a better carrier polymer to bind or encapsulate the drug for
delivery. The surfactant has a limit of how many organic/hydrophobic compounds it can contain
within the micelle during emulsion polymerization. As a result, the maximum amount of organic
content of the final emulsion is typically in the range of 15-20% by weight. This restricts the
usefulness of the nanoparticle as an effective drug carrier to 20% or less of the emulsion amount.
As previously noted, polyacrylate nanoparticle emulsions can be easily prepared through radicalinduced emulsion polymerization of butyl acrylate/styrene mixtures (7:3 w/w) in water at 78°C,
using sodium dodecyl sulfate (SDS) as an emulsifying agent and potassium persulfate as a
radical initiator (Figure 4.1).52,53
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Figure (4.1) Scheme for preparing poly(acrylate-styrene) emulsions.

The reactions led to the formation of a homogeneous, stable aqueous emulsion containing
uniformly-sized nanoparticles of 45-50 nm in diameter. The method was successfully applied to
penicillins and N-thiolated β-lactams, in which the antibacterial agents could be introduced into
the nanoparticle either by non-covalent entrapment as a free drug, or covalently via their acryloyl
derivative.

While these earlier nanoparticle emulsions provided increased water solubility and, in some
cases, improved bioactivity of the β-lactam antibacterial agent, the polyacrylate backbone was
largely comprised of the non-bioactive monomers (butyl acrylate-styrene or methyl
methacrylate-styrene (20% by weight of the emulsion), and thus only 1-3% (by weight) of the
nanoparticle framework was the antibacterial acrylate. Figure 4.1 shows the general scheme for
the formation of the nanoparticle emulsion, and the amount of drug loading into the nanoparticle
during the assembly process was limited by how much surfactant could be used, given that
amounts exceeding 3 mole % of SDS caused unwanted cytotoxicity. The final crude nanoparticle
emulsions contained up to 20% of solid content (a mixture of nanoparticles and a small amount
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of non-nanoparticle polymer), and only 0.2-0.6% of active antibacterial agent inside of the
nanoparticles. The resulting emulsions are typically milky in consistency and somewhat sticky
when exposed to air, causing films to form when dried, and forming coagulants within syringes,
micro-porous filters, and gel columns that made it very difficult to purify and use for in vivo
testing.

We were able to overcome some of these issues with purification techniques that enable the
removal of residual unreacted monomers and non-nanoparticle oligomers within the cloudy
emulsion. We also reported on the use of other surfactant combinations to try to enhance the
amount of antibiotic that could be entrapped, or to alter nanoparticle sizes, without increasing
overall cytotoxicity or instability of the emulsion. 5

Figure (4.2) Co-monomer-based encapsulation of antibiotic into polyacrylate nanoparticle
emulsions.

Figure 4.2 depicts the polyacrylate polymer that was formed that allows for the incorporation of
the bioactive drug either through covalently binding to the polymer backbone or encapsulating
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within the hydrophobic environment of the micelle. This in turn limits the amount of bioactive
drug that can be contained by the particle.

Aqueous Phase
Polymer backbone
Antibiotic
Surfactant
Enzyme

Organic Phase

Figure (4.3) Removal of co-monomers and formation of polymer via 100% of the acrylate
antibiotic analog.

Figure 4.3 shows that removing all acrylates except for the acrylated bioactive drug (or other
compound) for the emulsion polymerization would allow for an increase in the ability to load the
desired drugs/compounds within the micelles, and thus the final concentration in the nanoparticle
emulsion. If the same limit of 15-20% of organic material entrapped by the surfactant inside the
micelles is maintained, then the final concentration of the drug incorporated into the nanoparticle
would be considerably more than the typical 0.2%-0.6% achieved using the butyl
acrylate/styrene polyacrylate nanoparticles. The use of only N-acryloylciprofloxacin as the sole
monomer then would afford an advanced polyacrylate nanoparticle emulsion, which allows for
the delivery of higher drug content. This would in return require much smaller volumes of the
emulsion to be synthesized and used for drug delivery.
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In addition, we can expect to have similar results in reducing the cytotoxicity of the resulting
emulsions, as was observed for the homo poly(menthyl acrylate) nanoparticle emulsions
described in chapter three. In that case, the increased drug loading of penicillin G (up to 4% of
the final volume) allowed for a more diluted emulsion to be used to deliver the same amount of
penicillin G compared to the previous butyl acrylate/styrene polyacrylate nanoparticle emulsions.
The reduction in the concentration of sodium dodecyl sulfate required to make these emulsions
provided a dramatic reduction in cytotoxicity.

The avoidance of using other monomers for the nanoparticle formation additionally removes the
issue of unwanted coagulation and film formation previously observed for the poly(butyl
acrylate/styrene) nanoparticle emulsions. The residual styrene and butyl acrylate and nonparticle polymers that are not encapsulated within the surfactant could be removed by
centrifugation and dialysis, however, the resulting emulsions after purification still continued to
formed rubbery films when dehydrated, which clogged syringe needles and filtration
membranes. The use of these particular monomers was problematic in this regard and not using
them might eliminate the need to purify the ciprofloxacin acrylate emulsions.

In this chapter, a new approach to preparing antibiotic-bound polyacrylate nanoparticle
emulsions is investigated that completely obviates the restriction of using butyl acrylate and
styrene (or other co-monomers) to form the nanoparticle framework, and instead, uses the
antibiotic compound itself as the sole acrylate monomer for the polymerization. This technique
has never been reported and is thus an important advance in the polymer-based nanoparticle
field.
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For our studies, we chose ciprofloxacin as the antibiotic for the formation of the polyacrylate
nanoparticles. The N-acryloyl derivative of commercial ciprofloxacin hydrochloride was
prepared for this purpose according to our previously reported N-acylation procedure. 54,55

4.2 Synthesis of N-Acryloylciprofloxacin

Figure (4.4) Scheme for synthesis of N-acryloylciprofloxacin compound 9

Figure 4.4 shows the synthetic scheme for preparing N-acryloyl ciprofloxacin, and follows as
such: To a round bottom flask was added 120 ml of dichloromethane, then 3.0 g (9.0 mmol) of
ciprofloxacin and 1.8 ml (13.5 mmol) of triethylamine. The mixture was left stirring at 0 oC for 1
hour then acryloyl chloride (1.1 ml, 13 mmol) was added dropwise. The ice bath was removed
and the reaction was left stirring overnight. The dichloromethane was added dropwise to a flask
of hexane (200 ml) to cause a precipitate to form. The solid was collected by filtration and
allowed to air dry.

Yielded 2.90 g (83.7%) as a pale yellow solid. Melting point above 250 oC. 1H NMR (400 MHz,
CDCl3) δ 8.75 (s, 1 H), 8.03 (d, J = 12.8 Hz, 1 H), 7.36 (d, J = 7.1 Hz, 1 H), 6.60 (dd, J = 16.8,
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10.5 Hz, 1 H), 6.35 (dd, J = 16.8, 1.7 Hz, 1 H), 5.76 (dd, J = 10.5, 1.7 Hz, 1 H), 3.86 (m, 4 H),
3.52 (br. s., 1 H), 3.33 (m, 4 H), 1.38 (d, J = 6.2 Hz, 2 H), 1.19 (br. s., 2 H).

4.3 Formation of Poly(N-Acryloylciprofloxacin) Nanoparticle Emulsion

4.3.1 Attempted Preparation of Polyacrylate Emulsions
One of the main challenges with polymerizing the desired acryloyl analog of the bioactive drug
was that most of the previous antibiotics that were acrylated and loaded into the nanoparticle
emulsions were solids, and thus the liquid organic monomers of styrene and butyl acrylate could
be used to pre-dissolve the small amount of the solid acrylated antibiotic. This was also the case
with the poly(menthyl acrylate) nanoparticle emulsions, in that the non-bioactive monomer
menthyl acrylate was a liquid that allowed for the dissolution of the solid N-acryloyl
ciprofloxacin antibiotic in order to be incorporated into micelles during emulsion polymerization.

Attempts to use the same procedure for emulsion polymerization of the N-acrylated
ciprofloxacin monomer failed, however. Thus it was necessary to pre-dissolve the N-acryloyl
ciprofloxacin into an organic solvent that could easily be evaporated off during the
polymerization process or after the formation of the emulsions.

It was considered important to use a solvent of very low cytotoxicity to aid in the dissolution of
the bioactive compound, in case it would also load into the micelles along with the bioactive
compound. After experimentation with various common organic solvents, including methanol,
ethanol, propylene glycol, glycerol, and ethyl acetate; dichloromethane was chosen.
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4.3.2 Attempted Preparation of Homo Poly(N-N-Acryloylciprofloxacin) Nanoparticle
Emulsions Using Water-soluble Organic Solvents
Two liquid organic solvents were first used to aid the dissolution of N-acryloylciprofloxacin.
Propylene glycol and glycerin have very low cytotoxicity and due to their hydrophobic nature
would likely load into the surfactant-formed micelles, and thus potentially carry in with it the Nacryloylciprofloxacin. Though this technique would result in a co-solvent also being
incorporated into the micelles, it would still possibly allow for formation of the poly(Nacryloylciprofloxacin) emulsion.

However, the resulting emulsions formed from the use of these solvents were not homogeneous.
Due to glycerin’s high viscosity, it was very difficult to distribute and stir properly in the
aqueous media. This led to a bilayer, preventing homogeneous mixing of the resulting emulsion.
The mixture was heated up to 90°C in order to reduce the viscosity and allow for more uniform
stirring and mixing with water. However, the resulting emulsions remained non-homogeneous.

Propylene glycol provided a much better carrier solvent due to its lower viscosity. It was able to
form a more uniform emulsion and would require no modification in procedure compared to the
typical one used to make polyacrylate nanoparticle emulsions. However, the resulting emulsions
were unstable and formed a bilayer within minutes of being removed from the polymerization
conditions. The DLS data did confirm multiple populations of particles within the emulsion and
very low zeta potential values (-5 mV to -10 mV), which confirmed the inherent instability of the
emulsions. So these attempts did not prove effective.

79

4.3.3 Preparation of Homo Poly(N-Acryloylciprofloxacin) Nanoparticle Emulsions Using a
Water-insoluble Solvent
The other method investigated for polymerization of the solid N-acryloylciprofloxacin to be
evenly distributed within the aqueous mixture was to pre-dissolve the compound in an organic
solvent, and then remove the organic solvent via evaporation during the emulsion process or
after the emulsion formation. It was critical to completely remove the organic solvent, because
most organic solvents produce cytotoxicity.

This method was attempted using methanol, ethanol, ethyl acetate, and dichloromethane.
The main problem was the poor solubility of the N-acryloylciprofloxacin in most organic
solvents, except for dichloromethane. Up to 500 mg/ml of N-acryloylciprofloxacin could be
dissolved into dichloromethane. However, there was a critical issue that resulted with the
polymerization procedure. The typical procedure would call for the organics to be stirred at
75°C, then the surfactant and water are added in. This would cause the dichloromethane to
rapidly evaporate. Thus the starting temperature was adjusted to 25°C, and water and surfactant
were added to the stirring dichloromethane solution, however this resulted in an uneven
distribution and clumping of the surfactant. The result was a very sticky material that separated
from the water layer.

In order to solve this new issue, the surfactant and water were added first at 75°C so that the
surfactant may form micelles initially, and the dichloromethane solution was added dropwise.
However, this resulted in the near instant evaporation of the dichloromethane solvent, leaving
clumps of solid N-acryloylciprofloxacin unincorporated into the micelles. The final adjustment
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of the procedure is discussed in the following section, resulting in successful formation of the
emulsion.

4.3.4 Preparation of Poly(N-Acryloylciprofloxacin) Nanoparticle Emulsions

Figure (4.5) Scheme for preparing poly(N-acryloylciprofloxacin) nanoparticle emulsions

As seen in Figure 4.5, the polyacrylate emulsions were prepared using a modified protocol of the
usual nanoparticle emulsion technique used in our lab. The method to form the poly(Nacryloylciprofloxacin) emulsion required the following procedure: to a round bottom flask was
added 4 ml of deionized water, which was then stirred using a 1.25 cm (300 mg) Teflon-coated
magnetic stir bar at 1000 rpm on a Corning PC-420D magnetic stirrer at 30 oC using a selfregulated oil bath. To this was added 30 mg of SDS. N-Acryloylciprofloxacin (500 mg) was
dissolved in 1 ml of warm dichloromethane, and this solution was added dropwise to the
deionized water-SDS mixture. A vent was placed on top of the flask by inserting a small
stainless steel syringe needle through a rubber septum on the flask, under dry nitrogen, and the
temperature of the mixture was increased at a rate of 5 oC per 30 min until reaching 90oC. The
mixture was left stirring overnight at this temperature, under an atmosphere of dry nitrogen.
Potassium persulfate (10 mg) was added with an additional 0.5 ml of deionized water to the
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stirring mixture, and left stirring for 24 hours. The stirred emulsion was then removed from the
oil bath and decanted into a storage vial for analysis.

Figure (4.6) On the left, an example of a successful emulsion. On the right, two examples of
unsuccessful emulsions.

Figure 4.6 shows an example of a successful emulsion (on the left), forming a uniform single
layer emulsion, while previous attempted emulsions (the two on the right) show the results of an
unsuccessful emulsion polymerization.

4.4 Dynamic Light Scattering (DLS) Analysis
The first question we hoped to address was if any nanoparticles were being formed in the
emulsion polymerization process. For this, we used dynamic light scattering measurements. The
average size and surface charge of the emulsion was analyzed on a Malvern Zetasizer nano-ZS
instrument. To prepare the samples for the analyses, the freshly-made emulsion was subjected to
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centrifugation at 10,000 rpm for 5 min using an Eppendorf Centrifuge 5424. An aliquot of the
liquid emulsion was then drawn and deposited into a Malvern disposable folded capillary cell
DTS-1070. Each sample was analyzed in triplicate, and each data collection consisted of 1 run of
20 scans (for size analysis) and 3 runs of 100 scans (for zeta potential determination). The size
distribution shows a single narrow peak indicating the uniformity of the emulsion with a single
population centered on average at approximately 970 nm. Similarly, surface charge
measurements indicated a highly stable emulsion, with an average of -63 (+ 5.6) mV.

4.4.1 Dynamic Light Scattering (DLS) Analysis Results
As Figure 4.7 demonstrates, the dynamic light scattering experiments confirmed the presence of
a major population of nanoparticles in the emulsion, measuring on average approximately 970
nm in diameter. A general trend of increasing size was observed as the amount of Nacryloylciprofloxacin is increased in forming the polymer emulsions. In addition, the zeta
potential measurements showed that the particles carry a high surface charge of -63 (+ 5.6) mV.
This indicates the long-term stability of the emulsion. It is notable that these poly(Nacryloylciprofloxacin) nanoparticles are much larger than those previously constructed with
butyl acrylate-styrene co-monomers, which routinely measured 45-50 nm in diameter. The basis
for this 20-fold increase in size is not apparent at this time but deserves further investigation.
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Figure (4.7) Size of emulsified nanoparticles vs the % concentration of N-acryloylciprofloxacin
in the emulsions.

4.5 In vitro Antibacterial Testing
To investigate whether the nanoparticles possess antibiotic capabilities, each crude emulsion was
tested against Staphylococcus aureus (ATCC 25923) and Escherichia coli (K12) using a 96-well
plate broth assay to determine the minimum inhibitory concentration (MIC). Each assay was
done in triplicate.

The original stock emulsion was diluted using the Trypticase Soy Broth solution to an initial
concentration of 1.28 mg/ml of the N-acryloylciprofloxacin, then serial diluted with TSB to half
the concentration each time. A volume of 10 µl of each emulsion dilution was added to a well in
series, resulting in a final concentration run of 64 µg/ml to 0.012 µg/ml. The MIC was done in
triplicates for each bacterium, with ciprofloxacin hydrochloride being used as a positive control
and a blank of broth medium was used as a negative control.
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To prepare the bacteria for culture, all solutions were autoclaved prior to use. The bacteria were
grown overnight at 37oC on an agar plate composed of BBL TSA II Trypticase Soy Agar (TSA)
and BBL Trypticase Soy Broth (TSB) in a 1:2 ratio at 4.4% concentration. A broth solution of
2.4% TSB was inoculated using the bacteria from the agar plates, and incubated at 37 oC to reach
a 0.5 McFarland standard. The bacteria were then further diluted by a factor of 1000 using a
broth solution of 2.4% TSB, and 190 µl of the diluted bacterial solution was transferred by
micropipette into each well. The inoculated plates were incubated at 37 oC for 16-20 hours and
the resulting plates were observed for growth and MIC values recorded. The MIC was the lowest
concentration of the antibiotic that completely inhibited bacterial growth (visually) within that
series of dilutions.

4.5.1 Antibacterial Data for Poly (N-Acryloylciprofloxacin) Emulsions

Table (4.1) MIC values of ciprofloxacin and ciprofloxacin emulsion vs S. aureus and E. coli.
Sample

S.aureus (ATCC 25923)

E. coli (K12)

Control Ciprofloxacin

0.5 µg/ml

0.012 µg/ml

Poly (N-acryloyl-

0.5 µg/ml

0.012 µg/ml

ciprofloxacin) emulsion

The in vitro antibacterial studies showed that the nanoparticle emulsion was bioactive, with an
MIC of 0.5 µg/ml for S.aureus and 0.012 µg/ml against E.coli, identical to those of ciprofloxacin
itself (Table 4.1). The finding that these nanoparticles show antibacterial capabilities against both
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the gram-positive S.aureus and the gram-negative E.coli was surprising, given that particles of
such large dimensions would not be expected to be antibacterially active.

Ciprofloxacin must enter the bacterial cell to arrive at its target, bacterial DNA gyrase.
Attachment of the molecule to the polymer backbone of the nanoparticle requires it be released
through hydrolysis of the amide. This occurs either outside of the cell, or within the bacterium
itself if the nanoparticle can enter through the membrane. Most likely this requires enzymatic
release, as the amide functionality is a difficult one to cleave otherwise. Again, this is only
speculation that requires further investigation with proper controls, which are beyond the scope
of this study.

4.6 In Vitro Cytotoxicity of the Nanoparticle Emulsions
In vitro cell cytotoxicity was tested on two human cell lines, human colorectal carcinoma cells
HCT-116, and human embryonic kidney cells HEK 293. HCT-116 were grown in Dulbeco’s
Minimum Essential Medium (DMEM) with 10% fetal bovine serum and 0.1%
penicillin/streptomycin as a growth medium for several days at 37 oC under an atmosphere of 5%
CO2 to reach confluence. HEK 293 cells were grown in Eagle Minimum Essential Medium
(EMEM) with 10% fetal bovine serum and 0.1% penicillin/streptomycin as a growth medium for
several days at 37oC under an atmosphere of 5% CO2 to reach confluence. Each cell type was
then plated onto 96-well plates, at 50,000 cells per well at a volume of 150 µl with the respective
growth medium. The cells were counted using a hemocytometer and then incubated for 24 hours
at 37oC under an atmosphere of 5% CO2.
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The test emulsion was diluted using the growth medium for each cell type, and added into the
wells of each test plate to give a final concentration of N-acryloyl ciprofloxacin of 2 mg/ml, 1
mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, and 0.0625 mg/ml within a series. The testing was
done in triplicate and one well in each triplicate was left untreated as the negative control for
100% growth. The plates were further incubated and monitored for 48 hours at 37 oC under an
atmosphere of 5% CO2. A 5 mg/ml solution of 3-(4,5-dimethyl-2-thiazolyl)-2,5diphenyltetrazolium bromide (MTT) in sterile phosphate-buffered saline (PBS) was added to
give a 10% final concentration in each well. The plates were then further incubated for 4 hours at
37oC under an atmosphere of 5% CO2 to allow for the formation of the purple crystals of 1-(4,5dimethylthiazol)2-yl)-3,5-diphenylformazan. The liquid was then aspirated from each well and
100 µl of dimethylsulfoxide (DMSO) was added to each well, and gently shaken for 1 minute to
allow for complete dissolution of the crystals. The IC 50 value for the assay was determined using
a BioTek Synergy H1 hybrid plate reader at both 595 nm and 630 nm. The IC 50 was determined
as the well with at least 50% cell viability compared to the untreated control cell with 100% cell
growth.

4.6.1 Cytotoxicity Results for Poly(N-Acryloylciprofloxacin) Nanoparticle Emulsions
The in vitro cytotoxicity results for both human colorectal carcinoma cells HCT-116 and human
embryonic kidney cells HEK-293 were promising. The observed IC 50 was 500 µg/ml for both the
HCT-116 and HEK-293 cell lines, a 1000-fold difference over the bacterial MIC value for
S.aureus and greater than 40,000 for E.coli.
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4.7 Imaging Nanoparticle Emulsions Using a Scanning Electron Microscope
A sample of poly(N-acryloyl ciprofloxacin) nanoparticle emulsion was prepared for imaging
using scanning electron microscope. The samples was initially prepared by lyophylization of the
emulsion which resulted in a dry powder that could be added to the sample holder for the
scanning electron microscope instrument. The samples were placed onto an aluminum-coated
sample holding tape, mounted onto a copper tape, placed onto the scanning electron microscope
sample holder. The initial resulting image was very difficult to discern and it was most likely due
to the non-conductive nature of the material, causing the electrons to build up on the surface of
the material and distorting the image.

In order to resolve the issue, the sample was diluted 1000X with deionized water, and a drop of
the diluted emulsion was placed on the conductive aluminum-coated sample holding tape. The
sample was placed in the -80°C freezer for a few hours, then immediately lyophilized to dry the
sample right onto the sample holding tape to produce a more even distribution of the material.

In addition, the sample-containing tape was also sputter-coated with gold-palladium in order to
increase the conductivity of the resulting sample, thus preventing or reducing the accumulation
of electrons on the surface of the sample, and resulting in distortions.
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Figure (4.8) Scanning electron microscope image of the dried emulsion.

Figure (4.9) A zoomed in SEM image of a potential micelle within the emulsion.
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As observed in Figure 4.8 and Figure 4.9, the images from the scanning electron microscope do
not provide clear images of the spheres within the emulsion as were previously observed with
butyl acrylate/styrene and poly(menthyl acrylate) emulsions. This was thought to be the result of
the material continuing to building up charge on the surface, thus giving a distorted image.
Attempts to overcome this effect by ensuring a smooth and conductive surface for the sample
holding tape, and sputter-coating with conductive gold-palladium coating, did not improve
results. In addition, during the lyophilization process the spheres were dehydrated and deformed,
thus resulting in the spheres binding to each other and not remaining separate. This led to the
increase of the overall size when viewed from top down with the scanning electron microscope.

4.8 Discussion
Poly(N-acryloylciprofloxacin) nanoparticle emulsions were successfully prepared by
modification of the previously reported emulsion polymerization methodology. The main
difference with this new method was the need to dissolve the water-insoluble antibacterial agent
in an organic solvent to permit more uniform addition into the aqueous solution, in order to form
homogeneous emulsions. We found that dichloromethane provided the best combination of
solubilizing the ciprofloxacin monomer and being volatile enough to evaporate from the media
during emulsion polymerization at 90°C.

We also found that the increased temperature of 90°C rather than 75°C, an increased stir speed,
and the addition of sodium dodecyl sulfate before the organic monomers were added, provided
more optimal results. Additionally, we found it advantageous to let the reactions run for 48 hours
rather than the usual 6 hours required for the butyl acrylate-styrene co-monomer systems.
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These new procedures are required mainly due to the physical properties of the compounds
involved, and are pushing the limits and capabilities of the existing available equipment. Higher
loading of the drug could perhaps be possible if the mixture could be heated in a pressurized
system that would allow for a higher temperature to be achieved without boiling off the water. In
addition, a mechanical stirrer able to achieve a higher spin rate that the existing magnetic stir bar
method would most likely allow for additional loading of the monomer, since it would provide
more uniform distribution of large quantities of the solid monomer.

Lyophilization of the nanoparticle emulsion produced an amorphous powder that could not be
reformulated back to its original emulsified state through addition of water. Moreover, the
resulting powder remained insoluble in organic solvents including methanol, ethanol,
dichloromethane, hexane, acetone, ethyl acetate, and dimethylformamide. We did note that
extraction of the solid material with methanol, ethanol, dichloromethane, hexane, acetone, or
ethyl acetate failed to show any trace of unreacted N-acryloylciprofloxacin upon evaporation and
analysis by proton NMR spectroscopy. This confirms that the polymerization is complete, and
thus all of the N-acryloylciprofloxacin is incorporated into the framework of the nanoparticle.
Attempts to perform the emulsion polymerization procedure on the free ciprofloxacin instead of
the N-acryloyl derivative led to a bilayer mixture, not an emulsion, with the layers separating
within seconds after stirring was stopped. Additionally, the same procedure was attempted using
N-acetyl ciprofloxacin as an analog similar in structure but without the requisite olefin. Once
again, only an unstable mixture was formed, which that separated into layers with a few seconds
after stirring was stopped. Therefore, the acryloyl group is a prerequisite for emulsification and
subsequent nanoparticle formation.
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Though the field of antibacterial polymers is well explored, and various examples exist, they
typically rely on the use of other co-monomers to prepare the polymers. 35-38 This study is the first
involving an aqueous nanoparticle polymer emulsion being formed from a monomer that is the
antibiotic agent itself. The emulsion is formed via a one pot reaction in water and the final
antibiotic polymer is suspended in water. The emulsified nano-cipro particles are
antimicrobially-active towards gram positive S. aureus and gram negative E. coli. Our
laboratory hopes to further investigate the properties of the new “nanodrug” emulsions and to
further expand the possibilities with other, preferably water-insoluble, antibiotics for delivery
and effective treatment of drug-resistant bacterial infections.
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CHAPTER FIVE

FUTURE PROJECTS

Though several ends points have been reached with the body of work presented in this
dissertation, additional points of research still remain. The project in chapter 2 can be continued
through the use of poly(menthyl acrylate) nanoparticles emulsions that exhibit lower cytotoxicity
than poly(styrene-butyl acrylate) nanoparticle emulsion. The poly(menthyl acrylate)
nanoparticles emulsions can be further explored via covalent binding and encapsulating of
various antibiotics in order to study the limits of drug loading and delivery. The chiral properties
of poly(menthyl acrylate) nanoparticle emulsion can be further studied by loading enantiopure
bioactive compounds into the poly(L-menthyl acrylate) vs the poly(D-menthyl acrylate)
nanoparticle emulsion, and studying the difference in drug loading and drug delivery. Lastly, the
poly(N-acryloylciprofloxacin) nanoparticle emulsion could be further explored through the use
of alternative acryloyl derivatives of antibiotics, and used as the monomer to form homopolyacrylate antibacterial nanoparticle emulsions.

As of the publication of this dissertation, U.S Patent 09533051B2 was issued on January 2017
for the synthesis and drug delivery properties of poly(menthyl acrylate) nanoparticles. In
addition, after the completion of additional data points the work included in chapter 3 is to be
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submitted for publication in the spring of 2018. Research and results obtained in chapter 4
regarding poly(N-acryloylciprofloxacin) nanoparticle emulsion were submitted for publication in
Nanomedicine in November of 2017, along with filing for a provisional patent.
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CHAPTER SIX

EXPERIMENTAL PROCEDURES

DYNAMIC LIGHT SCATTERING DATA
NUCLEAR MAGNETIC RESONANCE SPECTRA
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DLS Data For 10 mg, Compound 2 Loaded Nanoparticle

96

DLS Data For 20 mg, Compound 2 Loaded Nanoparticle

97

DLS Data For 30 mg, Compound 2 Loaded Nanoparticle

98

DLS Data For 10 mg, Compound 3 Loaded Nanoparticle

99

DLS Data For 20 mg, Compound 3 Loaded Nanoparticle

100

DLS Data For 30 mg, Compound 3 Loaded Nanoparticle

101

DLS Data For D-Mta 10% Nanoparticle

102

DLS Data For D-Mta 20% Nanoparticle

103

DLS Data For D-Mta 30% Nanoparticle

104

DLS Data For D-Mta 40% Nanoparticle

105

DLS Data For D-Mta 50% Nanoparticle

106

DLS Data For D-Mta 60% Nanoparticle

107

DLS Data For D-Mta 70% Nanoparticle

108

DLS Data For D-Mta 80% Nanoparticle

109

DLS Data For D-Mta 90% Nanoparticle

110

DLS Data For D-Mta 100% Nanoparticle

111

DLS Data For L-Mta 10% Nanoparticle

112

DLS Data For L-Mta 20% Nanoparticle

113

DLS Data For L-Mta 30% Nanoparticle

114

DLS Data For L-Mta 40% Nanoparticle

115

DLS Data For L-Mta 50% Nanoparticle

116

DLS Data For L-Mta 60% Nanoparticle

117

DLS Data For L-Mta 70% Nanoparticle

118

DLS Data For L-Mta 80% Nanoparticle

119

DLS Data For L-Mta 90% Nanoparticle

120

DLS Data For L-Mta 100% Nanoparticle

121

DLS Data For Rac-Mta 10% Nanoparticle

122

DLS Data For Rac-Mta 20% Nanoparticle

123

DLS Data For Rac-Mta 30% Nanoparticle

124

DLS Data For Rac-Mta 40% Nanoparticle

125

DLS Data For Rac-Mta 50% Nanoparticle

126

DLS Data For Rac-Mta 60% Nanoparticle

127

DLS Data For Rac-Mta 70% Nanoparticle

128

DLS Data For Rac-Mta 80% Nanoparticle

129

DLS Data For Rac-Mta 90% Nanoparticle

130

DLS Data For Rac-Mta 100% Nanoparticle

131

DLS Data For 1% PenG Loaded D-Mta Nanoparticle

132

DLS Data For 2% PenG Loaded D-Mta Nanoparticle

133

DLS Data For 3% PenG Loaded D-Mta Nanoparticle

134

DLS Data For 4% PenG Loaded D-Mta Nanoparticle

135

DLS Data For 5% PenG Loaded D-Mta Nanoparticle

136

DLS Data For 6% PenG Loaded D-Mta Nanoparticle

137

DLS Data For 7% PenG Loaded D-Mta Nanoparticle

138

DLS Data For 8% PenG Loaded D-Mta Nanoparticle

139

DLS Data For 9% PenG Loaded D-Mta Nanoparticle

140

DLS Data For 10% PenG Loaded D-Mta Nanoparticle

141

DLS Data For 11% PenG Loaded D-Mta Nanoparticle

142

DLS Data For 12% PenG Loaded D-Mta Nanoparticle

143

DLS Data For 13% PenG Loaded D-Mta Nanoparticle

144

DLS Data For 14% PenG Loaded D-Mta Nanoparticle

145

DLS Data For 15% PenG Loaded D-Mta Nanoparticle

146

DLS Data For 16% PenG Loaded D-Mta Nanoparticle

147

DLS Data For 17% PenG Loaded D-Mta Nanoparticle

148

DLS Data For 18% PenG Loaded D-Mta Nanoparticle

149

DLS Data For 19% PenG Loaded D-Mta Nanoparticle

150

DLS Data For 20% PenG Loaded D-Mta Nanoparticle

151

DLS Data For 1% PenG Loaded L-Mta Nanoparticle

152

DLS Data For 2% PenG Loaded L-Mta Nanoparticle

153

DLS Data For 3% PenG Loaded L-Mta Nanoparticle

154

DLS Data For 4% PenG Loaded L-Mta Nanoparticle

155

DLS Data For 5% PenG Loaded L-Mta Nanoparticle

156

DLS Data For 6% PenG Loaded L-Mta Nanoparticle

157

DLS Data For 7% PenG Loaded L-Mta Nanoparticle

158

DLS Data For 8% PenG Loaded L-Mta Nanoparticle

159

DLS Data For 9% PenG Loaded L-Mta Nanoparticle

160

DLS Data For 10% PenG Loaded L-Mta Nanoparticle

161

DLS Data For 11% PenG Loaded L-Mta Nanoparticle

162

DLS Data For 12% PenG Loaded L-Mta Nanoparticle

163

DLS Data For 13% PenG Loaded L-Mta Nanoparticle

164

DLS Data For 14% PenG Loaded L-Mta Nanoparticle

165

DLS Data For 15% PenG Loaded L-Mta Nanoparticle

166

DLS Data For 16% PenG Loaded L-Mta Nanoparticle

167

DLS Data For 17% PenG Loaded L-Mta Nanoparticle

168

DLS Data For 18% PenG Loaded L-Mta Nanoparticle

169

DLS Data For 19% PenG Loaded L-Mta Nanoparticle

170

DLS Data For 20% PenG Loaded L-Mta Nanoparticle

171

DLS Data For 3% N-Acryloyl-5-ASA in Poly(L-Menthyl Acrylate) Nanoparticle Emulsion

172

DLS Data For 3% N-Acetyl-5-ASA in Poly(L-Menthyl Acrylate) Nanoparticle Emulsion

173

DLS Data For 1% N-Acryloyl Ciprofloxacin Nanoparticle Emulsion

174

DLS Data For 2% N-Acryloyl Ciprofloxacin Nanoparticle Emulsion

175

DLS Data For 3% N-Acryloyl Ciprofloxacin Nanoparticle Emulsion

176

DLS Data For 4% N-Acryloyl Ciprofloxacin Nanoparticle Emulsion

177

DLS Data For 5% N-Acryloyl Ciprofloxacin Nanoparticle Emulsion

178

DLS Data For 6% N-Acryloyl Ciprofloxacin Nanoparticle Emulsion

179

DLS Data For 7% N-Acryloyl Ciprofloxacin Nanoparticle Emulsion

180

DLS Data For 8% N-Acryloyl Ciprofloxacin Nanoparticle Emulsion

181

DLS Data For 9% N-Acryloyl Ciprofloxacin Nanoparticle Emulsion

182

DLS Data For 10% N-Acryloyl Ciprofloxacin Nanoparticle Emulsion
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1

H NMR (400 MHz, CDCl3) of N-acryloyl-5-ASA, (Compound 2)
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1

H NMR (400 MHz, CDCl3) of N-acetyl-5-ASA (Compound 3)
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1

H NMR (400 MHz, CDCl3) of L-menthyl acrylate (Compound 5)

186

1

H NMR (400 MHz, CDCl3) of D-menthyl acrylate (Compound 7)

187

1

H NMR (400 MHz, CDCl3) of N-acryloyl Ciprofloxacin (Compound 9)

188

LCMS of N-acryloyl Ciprofloxacin (Compound 9)
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APPENDIX A

MENTHOL-BASED NANOPARTICLES FOR DRUG DELIVERY

BACKGROUND OF THE INVENTION
There has been increasing interest within the scientific community in the use of
nanoparticles. With easily altered frameworks, these nanoparticles can be manipulated for
various properties and diverse applications. One area of focus is the study of nanoparticles as a
system for drug delivery. The growing antibiotic resistance of harmful microbes, such as
methicillin-resistant Staphylococcus aureus (MRSA), has emerged as one of the dominating
concerns of today’s public health system, causing scientists to look for ways to circumvent this
resistance through drug delivery methods and systems.

BRIEF SUMMARY OF THE INVENTION
Aspects of the present invention provide formulations comprising poly(menthyl acrylate)
nanoparticles comprising at least one active ingredient contained in a plurality of hydrophobic
carriers and dispersed in an aqueous medium.
In some embodiments, the at least one active ingredient is an antibiotic, such as but not
limited to, penicillin. The active ingredient can be from about 1% to about 20% (w/w) of the
formulation. In some embodiments, the hydrophobic carriers are made up of a surfactant, such as
but not limited to, sodium dodecyl sulfate (SDS). The hydrophobic carriers may form micelles
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dispersed in the aqueous medium such that the micelles encapsulate the poly(menthyl acrylate)
nanoparticles and active ingredient(s).
In one embodiment, the poly(menthyl acrylate) nanoparticles are poly(L-menthyl
acrylate) nanoparticles. In another embodiment, the poly(menthyl acrylate) nanoparticles are
poly(D-menthyl acrylate) nanoparticles.
Additional aspects of the present invention provide methods of polymerization of drug
loaded nanoparticles in an aqueous emulsion, comprising: adding a plurality of methyl acrylate
monomers to an aqueous medium; adding an active ingredient to the aqueous medium; adding a
surfactant to form the aqueous emulsion; and adding a radical initiator for alkene polymerization
of the methyl acrylate monomers in the presence of the active ingredient.
In some embodiments, the menthyl acrylate monomers are selected from L-menthyl
acrylate monomers, D-menthyl acrylate monomers, and a combination thereof.

BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows a diagram of the organization of nanoparticles of the invention within an
aqueous bulk media of the emulsion. Note: the antibiotic is not covalently bound to the polymer
backbone, allowing for easier release of the drug.
Figure 2 illustrates acrylate monomers of the present invention.
Figure 3 illustrates miniemulsion polymerization structures.
Figure 4 illustrates a miniemulsion polymerization process.
Figure 5 shows distribution of particle sizes and stability of nanoparticles of the present
invention.
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Figure 6A shows activity of penicillin and nanopenicillin particles of the present
invention on an agar plate.
Figure 7 is a graph showing that the nanoparticle emulsions have optical activity and that
the specific rotation values are somewhat non-linear.
Figure 8 shows the process of polymerization of nanoparticles from polyacrylate
monomers.
Figure 9 shows a graph of the distribution of particle sizes of various chiral nanoparticle
samples of the present invention.
Figure 10 shows a graph of the distribution of zeta potentials of various chiral
nanoparticle samples of the present invention.
Figure 11 shows a graph of the optical rotation versus concentration for the
polyacrylated nanoparticle emulsions of the present invention.
Figure 12 illustrates menthyl acrylate monomers and acrylate nanoparticle emulsions of
the present invention.
Figure 13 illustrates a method of measuring size and stability of nanoparticles utilizing
dynamic light scattering.
Figure 14 shows a graph of the size distribution of penicillin encapsulated nanoparticles
in nanoparticle emulsions of the present invention.
Figure 15 shows a graph of the zeta potentials of penicillin encapsulated nanoparticles in
nanoparticle emulsions of the present invention.
Figure 16 shows a graph of the optical activity of penicillin encapsulated nanoparticles in
nanoparticle emulsions of the present invention.
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Figure 17A shows emulsions of L-menthyl acrylate with drug load concentrations of 0%
to 20% of Pen G by weight (shown top) and those of D-menthyl acrylate with loads ranging from
1% to 20% of Pen G by weight (shown bottom); Figure 17B shows examples of failed
emulsions. Note: the D-menthyl samples were more destabilized and crashed out.

DETAILED DISCLOSURE OF THE INVENTION
The present invention provides the chemical synthesis and characterization of organic
nanoparticles using menthyl acrylate as a monomer in emulsion polymerization. Either the D- or
the L-stereomeric form of menthyl acrylate can be used as a means to produce homochiral
polyacrylate nanoparticles in an aqueous emulsion. The present invention further provides the
use of these nanoparticles to uptake chiral drug molecules (active ingredients), such as penicillin
G, non-covalently, through encapsulation, at much higher concentrations compared to nonmenthyl acrylate based nanoparticle formulations, as illustrated in Figure 1. Additionally, the
nanoparticles can be made and/or utilized without containing an “active ingredient”.
Reference is made herein to particular features (including method steps) of the invention.
Where a particular feature is disclosed in the context of a particular aspect or embodiment of the
invention, that feature can also be used, to the extent possible, in combination with and/or in the
context of other particular aspects and embodiments of the invention, and in the invention
generally.
The term “comprises” is used herein to mean that other ingredients, components, steps,
etc. are optionally present. When reference is made herein to a method comprising two or more
defined steps, the steps can be carried out in any order or simultaneously (except where the
context excludes that possibility), and the method can include one or more steps which are
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carried out before any of the defined steps, between two of the defined steps, or after all of the
defined steps (except where the context excludes that possibility).
This invention may be embodied in many different forms and should not be construed as
limited to the embodiments set forth herein. Rather, these embodiments are provided so that this
disclosure will convey preferred embodiments of the invention to those skilled in the art.
Aspects of the present invention provide formulations comprising poly(menthyl acrylate)
nanoparticles comprising at least one active ingredient contained in a plurality of hydrophobic
carriers and dispersed in an aqueous medium.
As used herein, the term "pharmaceutically active ingredient" or "active ingredient"
means an ingredient in the formulation that produces a physiological effect in the user. Active
ingredients include, but are not limited to, antibiotics, analgesics, anti-inflammatories,
stimulants, depressants, sedatives, electrolytes, vitamins, minerals, hormones, peptides, nucleic
acids, or any other pharmaceutically active substances and drugs. In some embodiments, the at
least one active ingredient is an antibiotic, such as but not limited to, penicillin. The active
ingredient can be from about 1% to about 20% (w/w) of the formulation; however, the
concentration range may be expanded or contracted, depending on the particular active
ingredient.
In some embodiments, the hydrophobic carriers are made up of a surfactant, such as but
not limited to, sodium dodecyl sulfate (SDS). The hydrophobic carriers may form micelles
dispersed in the aqueous medium such that the micelles encapsulate the poly(menthyl acrylate)
nanoparticles and active ingredient(s). Generally, the hydrophobic carriers comprise amphiphilic
properties. A micelle is formed from amphiphilic molecules. When dispersed in an aqueous
solution, the hydrophilic head groups form a hydrophobic pocket composed of the hydrophobic
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tail groups. One or more active ingredients and nanoparticles may be encapsulated by the micelle
in the hydrophobic pocket.
In one embodiment, the poly(menthyl acrylate) nanoparticles are poly(L-menthyl
acrylate) nanoparticles. In another embodiment, the poly(menthyl acrylate) nanoparticles are
poly(D-menthyl acrylate) nanoparticles.
Additional aspects of the present invention provide methods of polymerization of drug
loaded nanoparticles in an aqueous emulsion, comprising: adding a plurality of methyl acrylate
monomers to an aqueous medium; adding an active ingredient to the aqueous medium; adding a
radical initiator for alkene polymerization of the methyl acrylate monomers in the presence of the
active ingredient; and adding a surfactant to form the aqueous emulsion.
Generally, a plurality of methyl acrylate monomers is dispersed in an aqueous medium.
Then, the active ingredient is dispersed into the medium containing the monomers. Next, a
surfactant is added to the aqueous medium to form an emulsion containing micelles
encapsulating the nanopolymer-active ingredient mix. Finally, alkene polymerization is initiated
to generate the nanopolymers in the presence of the active ingredient.

In some

embodiments, the menthyl acrylate monomers are selected from L-menthyl acrylate monomers,
D-menthyl acrylate monomers, and a combination thereof. In additional embodiments, the
emulsions of the present invention can also contain variable ratios of styrene as a co-monomer
for polymerization.
In some embodiments, the emulsions of the present invention comprise butyl acrylate
with styrene (no menthyl acrylate). In some embodiments, the emulsions of the present invention
comprise L-menthyl acrylate with styrene. In some embodiments, the emulsions of the present
invention comprise D-menthyl acrylate with styrene. In some embodiments, the emulsions of
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the present invention comprise racemic menthyl acrylate with styrene. Additionally, the
emulsions may comprise about 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 w/w% of menthyl
acrylate relative to styrene.

All patents, patent applications, provisional applications, and publications referred to or
cited herein are incorporated by reference in their entirety, including all figures and tables, to the
extent they are not inconsistent with the explicit teachings of this specification.
Following are examples that illustrate procedures for practicing the invention. These
examples should not be construed as limiting. All percentages are by weight and all solvent
mixture proportions are by volume unless otherwise noted.

EXAMPLE 1—Analysis studies of enantiomerically pure polyacrylate nanoparticles
Purely organic chiral nanoparticles were synthesized from polyacrylates. Polyacrylates
contain a large diverse group of potential monomers, each with readily tunable physical
properties. Chirality was imparted via polymerization of styrene (St) with chiral monomer, Lmenthyl acrylate (L-Mta) (Figure 2). The L-Mta was synthesized as follows:
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The mechanism behind the nanoparticle formation is miniemulsion polymerization.
Surfactants behave as reaction vesicles to contain the polymerization (Figure 3). The chirality
may be tailored by varying the chiral monomer and its concentration.
Six samples of poly (MtA-co-St) nanoparticles were synthesized using 10, 20, 30, 40, 50,
and 60 v/v% of MtA relative to St (Figure 4).
As shown in Tables 1 and 2, poly(MtA-co-St) form as stable nanoparticle emulsions in
water.

Table 1: Nanoparticle emulsions

Table 2: Zeta potential provide stability guidelines for colloids

Optical activity was determined by polarimetry and particle size, stability, and
polydispersity determined by dynamic light scattering. The distribution of particle size and
particle stability is shown in Figure 5.
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The bioactivity was tested by Kirby-Bauer diffusion assay against Staphylococcus
aureus. Figure 6 shows that both penicillin and the nanopenicillins are active (clear areas on the
agar), while only the nanopenicillins are active when β-lactamase protein is added to the growth
media. Figure 7 shows that the nanoparticle emulsions have optical activity and, thus, are chiral
and that the specific rotation values are somewhat non-linear.

EXAMPLE 2—Analysis of emulsion stability and uniformity of chiral polymer
nanoparticles.
In this example, the particle size and zeta potential are characterized for optically active
polyacrylate nanoparticles derived from D- and L- menthyl acrylate.

D-menthyl acrylate

L- menthyl acrylate

The enantiomerically-pure acrylates of D- and L-menthol were synthesized by reaction
with acryloyl chloride in the presence of triethylamine.
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The chiral nanoparticles were then synthesized by emulsion polymerization of the D- and
L-menthyl acrylates, using styrene as a co-monomer at 78 degrees Celsius. Potassium persulfate
was used as a radical initiator and sodium dodecyl sulfate (SDS) was added as a surfactant to
stabilize the nanoparticles (Figure 8). A summary of the reagents and the necessary amounts for
the synthesis of a 2.5 mL emulsion sample at 3% drug load concentration is shown in Table 3.

Table 3.

Six series of nanoparticle samples were prepared for physical characterization:
(1) butyl acrylate with styrene (no menthyl acrylate)
(2) L-menthyl acrylate with styrene
(3) D-menthyl acrylate with styrene
(4) racemic menthyl acrylate with styrene
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Each of these four series contained ten samples with 10, 20, 30, 40, 50, 60, 70, 80, 90,
and 100 w/w% of menthyl acrylate relative to styrene.

(5) nanoparticles made by polymerizing mixtures of the enantiomeric pure acrylates, in
ratios from 90:10 D:L to 10:90 D:L (BE “before emulsification”) (no styrene)
(6) nanoparticles made by mixing different amounts of each enantiomeric pure
nanoparticle emulsion, in ratios from 90:10 D:L to 10:90 D:L (AE “after emulsification”)” (no
styrene)
Each of these two series contained 9 samples with 10, 20, 30, 40, 50, 60, 70, 80, and 90
w/w% of D-menthyl acrylate relative to L-menthyl acrylate.
For each of the nanoparticle samples, dynamic light scattering was used to analyze the
particle size, uniformity, and stability, in triplicates. The data for each of these are presented in
Figures 9 and 10. The particle size is measured in nanometers (nm), which includes the
nanoparticle as well as the surface hydration sphere. The narrowness of size distribution ensures
that the nanoparticles are uniform in size. A large zeta potential value greater than 60 mV
indicates the emulsion is very stable and does not precipitate (see Table 2).
This example demonstrates that chiral polyacylate nanoparticles can be synthesized by
using enantiomerically pure menthyl acrylates as monomers. There were no significant
differences observed in the particle sizes or stabilities as the amounts of chiral monomers were
varied. The particle sizes ranged from 40-60 nm among all series, and the zeta potentials were in
the range of -30 to -50 mV, indicating high stability in aqueous emulsions.
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EXAMPLE 3—Study of the optical properties of chiral polyacrylate nanoparticles
synthesized from D- and L-menthyl acrylate.
In this example, chirality is added to the framework using enantiomerically-pure acrylates
of D- and L-menthol as shown below, and the optical properties of the chiral nanoparticles are
characterized by polarimetry and circular dichroism.

D-menthyl acrylate

L- menthyl acrylate

The enantiomerically-pure acrylates of D- and L-menthol were synthesized by reaction
with acryloyl chloride in the presence of triethylamine.

With the L-menthyl acrylate and D-menthyl acrylate being used as monomers, different
nanoparticles were prepared using varying amounts of each chiral acrylate, from 0% to 100% by
weight. The acrylate and styrene were used as co-monomers to construct the nanoparticles by
free radical polymerization in aqueous solution.
Ten samples of each nanoparticle emulsion were synthesized with the varying ratios by
w/w% of the chiral acrylate monomer and the styrene. Each sample was then diluted 200 times
for measurements in both the polarimeter and CD.
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Optical activity was determined by optical polarimetry and circular dichroism (CD). All
optical rotation measurements on the polarimeter were recorded at 589 nm. A range of 195-250
nm at 1 nm intervals was used for the CD (data not shown).
A perfectly linear relationship was expected between the angle of rotation and
concentration. However, as shown in Figure 11, there was a slight deviation from linearity
between the 60-70 w/w% for the D and L enantiomeric particles. Also in the graph, the line
labeled BE (Before Emulsion) is for nanoparticle samples containing mixtures of both
enantiomeric acrylates, in ratios ranging from 10D:90L to 90D:10L, prepared by emulsion
polymerization of the two chiral acrylates. The line labeled AE (After Emulsion) is for
nanoparticle samples consisting of mixtures of enantiomerically pure nanoparticle emulsions
(each made from the individual menthyl acrylate enantiomers) ranging from 10D:90L to
90D:10L. Neither of the BE and AE sets contained styrene but only the menthyl acrylate. These
sets were synthesized to show that there is no significant difference between mixing the
enantiomeric monomers then polymerizing to make the emulsions, versus mixing the pre-made
chiral nanoparticle emulsions. The optical properties are similar for both samples.
This example shows that chiral polyacrylate nanoparticles can be synthesized by
emulsion polymerization using enantiomerically pure menthyl acrylates as monomers. The
optical activity of these chiral polyacrylated nanoparticles was analyzed using polarimetry. It
was found that the optical rotation values of the nanoparticles slightly deviated from linearity for
those samples having 60-70 w/w% of either D-menthyl acrylate or L-menthyl acrylate. The
alternative methods used to make the BE and AE sets showed no significant differences in the
optical properties of the chiral polyacrylated nanoparticles.
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EXAMPLE 4—Study of the stability and uniformity of enantiomerically-pure penicillin
encapsulated poly(menthyl acrylate) nanoparticle emulsions.
In order to synthesize the menthol derived polymers, L-menthol and D-menthol were
individually reacted with acryloyl chloride along with triethylamine to create the single chiral
unit that makes up the polymer chain. The polymer framework was prepared using potassium
persulfate as the radical initiator for the alkene polymerization. To make the emulsion, the
polymer is set in the presence of the surfactant sodium dodecyl sulfate (SDS) and water (Figure
12).
Nanoparticle behavior has been the subject of great scrutiny because while many methods
have proven to be viable for analysis, dynamic light scattering (DLS) is one of the few that is
non-destructive and employs simple methods (Livingstone, 2012). In order to analyze the
nanoparticles, a beam of light is passed through the particle sample that produces a signal
according to the changes in scattering intensity (Figure 13). The scattering intensity of the
sample reflects the constant movement of the nanoparticles (Livingstone, 2012).
Zeta potentials are very useful tools for the measurement of stability because they can
quantify the charge repulsion or attraction between the particles involved in a liquid environment
(Wang et al., 2013). Since the emulsion involves two liquids of different miscibility, the zeta
potential of the encapsulated nanoparticles can be measured using a zetasizer that uses dynamic
light scattering technology (Sarker, 2013). Zeta potentials can be analyzed for particle uniformity
and stability based on their numerical range (Table 2). Additionally, DLS can help quantify
particle size.
Each sample was prepared by encapsulating different percentages of Penicillin G within the
polymer framework. The different samples were loaded starting with 1% Pencillin G (by weight)
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and the percentage of the antibiotic was increased by 1% in each new sample all the way up to
20% (Table 4). Each particle size including the emulsion was calculated by taking the average of
3 sample sizes in nanometers (nm). The zeta potential is the average of triplicate samples, in
millivolts (mV). Furthermore, to ensure chirality was maintained the optical rotation of the
nanoparticles was measured through

polarimetry.

Table

4. *Data average included from partial emulsion **Data averageset includes samples with no
emulsion
As illustrated in Figure 14, most of the nanoparticles were less than 100nm. When
comparing the D- and L-menthyl acrylate systems, the nanoparticle emulsions prepared using Lmenthyl acrylate were more consistent in size, even when the percentage of Penicillin G was
higher. Alternatively, the size of the D-menthyl-derived particles fluctuated in comparison, yet at
the highest percentage of PenG, the nanoparticle was well within the range of the L-menthol
sample prepared with the same percentage of PenG.
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Zeta Potentials for both D- and L-menthyl nanoparticle emulsions (Figure 15) showed
consistent uniformity and stability with most zeta potentials being at least moderately stable. The
zeta potentials for both D- and L-menthyl were as high as -24 mV but peaked at ~-63 mV on the
nanoparticle made with L-menthyl. D-menthyl, however, did still show high uniformity with a
particle having a value of ~-100 mV.

Table 5.

The optical rotation values of the nanoparticles were more consistent for the L-menthyl
samples, which did not show a significant drop in activity at PenG concentrations of 11-15%
(Figure 16). However, the average rotation values for the D-menthyl samples were greater in
magnitude than that of the L-menthyl samples (Table 5).
Since both D- and L-menthyl acrylate nanoparticles had zeta potentials ranging from ~24mV to ~-100mV, the synthesized nanoparticle emulsions were consistently uniform and stable
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in the aqueous media. Even while the percentage of PenG increased, the uniformity of the
particle remained consistent and particles such as the D-menthyl that contained 17% PenG had
an excellent zeta potential close to -100mV. While most of the tested samples appeared as single
layers, one nanoparticle polymer was not emulsified D-menthyl with 19% Pen G. Additionally,
some samples had partial emulsions, but the zeta potential of the nanoemulsion layer still
supported uniformity. Based on the data acquired and visible uniformity of the emulsions, Lmenthyl acrylate nanoparticles were more uniform. Varying zeta potentials among both menthyl
enantiomers could be the subject of future study, however, based on collected data, both D- and
L-menthyl acrylate nanoparticle emulsions act as viable systems for drug delivery.
The resultant nanoparticle emulsions were found to be stable both in size and zeta
potential when analyzed via dynamic light scattering (DLS). There is also a definite hue to be
noted as the concentration of the drug load increases in the system (Figure 17A). Additionally, it
was noted that D-menthyl acrylate emulsions were more likely to destabilize than L-menthyl
acrylate emulsions (Figure 17B).
This study demonstrated the successful synthesis of antibiotic carrying nanoparticle
emulsions using a polyacrylate backbone system composed of enantiomerically pure D- and Lmenthyl acrylates of up to 20% by weight. Characterization of size and stability via DLS analysis
found these particles to be 100 nm in diameter, and having zeta potentials of roughly -50 mV for
both enantiomers. The polarimetry measurements for optical rotation were found to be rather
inconsistent across the D-Menthyl samples, with a significant drop in activity between drug load
concentrations of 11-15%, and the optical activity of the L-Menthyl samples were notably
smaller in magnitude than its enantiomeric counterpart. This could be due to the large dilution
factor at which these samples are prepared, which introduces a large margin of error. It is also
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possible that the varying lengths of the polymer present in each sample had an effect on the
optical activity. There were some minor destabilizing effects observed in the D-Menthyl samples
in comparison to the L-Menthyl samples.
It should be understood that the examples and embodiments described herein are for
illustrative purposes only and that various modifications or changes in light thereof will be
suggested to persons skilled in the art and are to be included within the spirit and purview of this
application and the scope of the appended claims. In addition, any elements or limitations of any
invention or embodiment thereof disclosed herein can be combined with any and/or all other
elements or limitations (individually or in any combination) or any other invention or
embodiment thereof disclosed herein, and all such combinations are contemplated with the scope
of the invention without limitation thereto.
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CLAIMS
We claim:
1. A formulation comprising poly(menthyl acrylate) nanoparticles comprising at least
one active ingredient contained in a plurality of hydrophobic carriers dispersed in an aqueous
medium.

2. The formulation of claim 1, wherein the at least one active ingredient is an antibiotic.
3. The formulation of claim 1, wherein the at least one active ingredient is penicillin.
4. The formulation of claim 1, wherein the at least one active ingredient is about 1% to
about 20% (w/w) of the formulation.
5. The formulation of claim 1, wherein the plurality of hydrophobic carriers are a
surfactant.
6. The formulation of claim 1, wherein the plurality of hydrophobic carriers form
micelles dispersed in the aqueous medium.
7. The formulation of claim 1, wherein the poly(menthyl acrylate) nanoparticles are
poly(L-menthyl acrylate) nanoparticles.
8. The formulation of claim 1, wherein the poly(menthyl acrylate) nanoparticles are
poly(D-menthyl acrylate) nanoparticles.
9. A method of polymerization of drug loaded nanoparticles in an aqueous emulsion,
comprising:
adding a plurality of methyl acrylate monomers to an aqueous medium;
adding an active ingredient to the aqueous medium;
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adding a radical initiator for alkene polymerization of the methyl acrylate monomers in
the presence of the active ingredient; and
adding a surfactant to form the aqueous emulsion.
10. The method of claim 9, wherein the menthyl acrylate monomers are L-menthyl
acrylate monomers.
11. The method of claim 9, wherein the menthyl acrylate monomers are D-menthyl
acrylate monomers.
12. The method of claim 9, wherein the menthyl acrylate monomers are selected from Lmenthyl acrylate monomers, D-menthyl acrylate monomers, and a combination thereof.
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ABSTRACT OF THE DISCLOSURE
The subject invention pertains to formulations comprising poly(menthyl acrylate)
nanoparticles comprising at least one active ingredient contained in a plurality of hydrophobic
carriers and dispersed in an aqueous medium. The subject invention further pertains to methods
of polymerization of drug loaded nanoparticles made up of methyl acrylate monomers in an
aqueous emulsion.
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APPENDIX B
CIPROFLOXACIN-BASED POLYACRYLATE NANOPARTICLE FOR ANTIBACTERIAL
APPLICATIONS

Abstract
We investigate for the first time a method for forming polyacrylate nanoparticles using Nacryloyl ciprofloxacin for its construction. The procedure entails a free radical induced emulsion
polymerization of the ciprofloxacin acrylate as the sole monomer in water to produce a stable
emulsion containing nanoparticles of highly uniform size and morphology with an average
diameter of 970 nm and average surface charge of -63 mV. The nanoparticles were found to be
capable antibacterials with minimum inhibitory concentration values against Staphylococcus
aureus and Escherichia coli comparable to that of free ciprofloxacin, with essentially no
observable cytotoxicity.

Keywords: ciprofloxacin, homopolymer, emulsion, nanoparticle, drug delivery, antibacterial
polymer

229

Background
Previous experiments in our laboratory have demonstrated the ability to form aqueous
polyacrylate nanoparticle emulsions for the purpose of water-solubilizing and encasing certain
antibacterial compounds, as a means to improve their stability and antibiotic activity especially
towards multi-drug resistant strains of bacteria. These nanoparticle emulsions were prepared
through radical-induced emulsion polymerization of butyl acrylate/styrene mixtures (7:3 w/w) in
water at 600C, using sodium dodecyl sulfate (SDS) as an emulsifying agent and potassium
persulfate as a radical initiator (Figure 1).1-4 The reactions led to the formation of a
homogeneous, stable aqueous emulsions containing uniformly-sized nanoparticles of 45-50 nm
in diameter. The method was successfully applied to penicillins and N-thiolated β-lactams, and
such that the antibacterial agents could be introduced into the nanoparticle either by non-covalent
entrapment as a free drug, or covalently via their acryloyl derivative. The antibiotic-containing
nanoparticles show promising in vitro activity against pathogenic bacteria such as methicillinresistant Staphylococcus aureus (MRSA).
(INSERT FIG1.DOCX)
While these earlier nanoparticle emulsions provided increased water solubility and, in some
cases, improved bioactivity of the β-lactam antibacterial agent, the polyacrylate backbone was
largely comprised of non-bioactive monomers (butyl acrylate-styrene or methyl methacrylatestyrene), and only 1-3 % (by weight) of the antibacterial acrylate in the nanoparticle. The amount
of drug loading into the nanoparticle during the assembly process was limited by how much
surfactant could be used, given that amounts exceeding 3 % (by weight) of SDS caused
discernable cytotoxicity. The nanoparticle emulsions contained up to 20% of solid content (a
mixture comprising of nanoparticles and a small amount of non-surfactated polymers), 80%
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water, and 0.2-1% of active antibacterial agent inside of the nanoparticles. The resulting
emulsions were typically milky in consistency and somewhat sticky when exposed to air, causing
films to rapidly form when dried, and unwanted coagulation within syringes, micro-porous
filters, and gel columns that made it very difficult to purify and use for in vivo testing. We were
able to overcome some of these issues with purification techniques that enable the removal of
residual unreacted monomers and non-nanoparticle oligomers within the emulsion. We also
reported on the use of other surfactant combinations to try to enhance the amount of antibiotic
that could be entrapped, or to alter nanoparticle sizes, without increasing overall cytotoxicity or
instability of the emulsion. 5
In this report, we describe an altogether new approach to preparing antibiotic-bound polyacrylate
nanoparticle emulsions that completely obviates the restriction of using butyl acrylate and
styrene (or other monomers) to form the nanoparticle framework, and these limitations in their
properties. The new procedure uses the antibiotic compound itself as the sole acrylate monomer
for the polymerization. This technique has never been reported and is thus an important advance
in the polymer-based nanoparticle field.
Methods
For our studies, we chose ciprofloxacin as the antibiotic for the formation of the polyacrylate
nanoparticles. The N-acryloyl derivative of commercial ciprofloxacin hydrochloride was
prepared for this purpose according to our previously reported acylation procedure. 6-7
(INSERT FIG2.DOCX)
Figure 2 shows the synthetic scheme for N-acryloylciprofloxacin, and follows as such: To a
round bottom flask was added 120 ml of dichloromethane, then 3.0 g (9.0 mmol) of
ciprofloxacin and 1.9 ml (13.5 mmol) of triethylamine. The mixture was left stirring at 0 oC for 1
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hour then acryloyl chloride (1.1 ml, 13 mmol) was added dropwise. The ice bath was removed
and the reaction was left stirring overnight. The solution was added dropwise to a flask of
containing hexane (60-80 ml) and the resulting solid was collected by filtration and allowed to
air dry.
Yielded 2.90 g (83.7%) as a pale yellow solid. Melting point above 250 oC. 1H NMR (400 MHz,
CDCl3) δ 1.18 (br. s., 2 H) 1.38 (d, J=6.6 Hz, 2 H) 3.33 (m, 4 H) 3.51 (br. s., 1 H) 3.47 (m, 1 H)
3.86 (m, 4 H) 5.76 (dd, J=10.5, 1.7 Hz, 1 H) 6.35 (dd, J=16.8, 1.7 Hz, 1 H) 6.59 (dd, J=16.8, 10.5
Hz, 1 H) 7.35 (d, J=7.1 Hz, 1 H) 8.03 (d, J=12.8 Hz, 1 H) 8.75 (s, 1 H)
(INSERT FIG3.DOCX)
The polyacrylate emulsions were prepared using a modified protocol to that we previously
reported.1,2 As seen in Figure 3 the method for forming the poly(N-acryloylciprofloxacin)
emulsion requires the following procedure: to a round bottom flask was added 4 ml of deionized
water, which was then stirred using a 1.25 cm (300 mg) Teflon-coated magnetic stir bar at 1000
rpm on a Corning PC-420D magnetic stirrer at 30 oC using a self-regulated oil bath. To this was
added 30 mg of SDS. N-Acryloylciprofloxacin (500 mg) was dissolved in 1 ml of warm
dichloromethane, and this solution was added dropwise to the DI water-SDS mixture. A vent was
placed on top of the flask by inserting a small stainless steel syringe needle through a rubber
septum on the flask, under dry nitrogen, and the temperature of the mixture was increased at a
rate of 5 oC per 30 min until reaching 90 oC. The mixture was left stirring overnight at this
temperature, under an atmosphere of dry nitrogen. Potassium persulfate (10 mg) was added with
an additional 0.5 ml of deionized water to the stirring mixture and left stirring for an additional
24 hours. The stirred emulsion was then removed from the oil bath and decanted into a storage
vial for analysis.
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The first question we hoped to address was whether any nanoparticles were being formed in the
emulsion polymerization process. For this, we used dynamic light scattering analysis to evaluate
the average size and surface charge of the emulsion using a Malvern Zetasizer nano-ZS
instrument. To prepare the samples for the analyses, the freshly-prepared emulsion was subjected
to centrifugation at 10,000 rpm for 5 min using an Eppendorf Centrifuge 5424. An aliquot of the
liquid emulsion was then drawn and deposited into a Malvern disposable folded capillary cell
DTS-1070. Each sample was analyzed in triplicate, and each data collection consisted of 1 run of
100 scans (for size analysis) and 3 runs of 100 scans (for zeta potential determination). The size
distribution shows a single narrow peak indicating the uniformity of the emulsion with a single
population centered on average at approximately 970 nm. Similarly, surface charge
measurements indicated a highly stable emulsion, with an average reading of -63 (+ 5.6) mV.
To investigate whether the nanoparticles possess antibiotic capabilities, each crude emulsion was
tested against Staphylococcus aureus (ATCC 25923) and Escherichia coli (K12) using a 96-well
plate broth assay to determine the minimum inhibitory concentration (MIC).
The original stock emulsion was diluted using the above Trypticase Soy Broth solution to an
initial concentration of 1.28 mg/ml of the N-acryloylciprofloxacin, then serial diluted with TSB
to half the concentration each time. A volume of 10 µl of each emulsion dilution was added to a
well in series, resulting in a final concentration run of 64 µg/ml to 0.012 µg/ml. The MIC was
done in triplicates for each bacterium, with ciprofloxacin hydrochloride being used as a positive
control and a blank broth used as a negative control.
To prepare the bacteria for culture, all solutions were autoclaved prior to use. The bacteria were
grown overnight at 37oC on an agar plate composed of BBL TSA II Trypticase Soy Agar (TSA)
and BBL Trypticase Soy Broth (TSB) in a 1:2 ratio at 4.4% concentration. A broth solution of
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2.4% TSB was inoculated using the bacteria from the agar plates, and was incubated at 37 oC to
reach a 0.5 McFarland standard. The bacteria was then further diluted by a factor of 1000 using a
broth solution of 2.4% TSB, and 190 µl of the diluted bacterial solution was transferred by
micropipette into each well. The inoculated plates were incubated at 37 oC for 16-20 hours and
the resulting plates were observed for growth and MIC values recorded. The MIC was the lowest
concentration of the antibiotic that completely inhibited bacterial growth (visually) within that
series of dilutions.
In vitro cell cytotoxicity was tested on two human cell lines, human colorectal carcinoma cells
HCT-116, and human embryonic kidney cells HEK 293. HCT-116 were grown in Dulbeco’s
Minimum Essential Medium (DMEM) with 10% fetal bovine serum and 0.1%
penicillin/streptomycin as complete growth medium for several days at 37 oC and 5% CO2 to
reach confluence. HEK 293 cells were grown in Eagle Minimum Essential Medium (EMEM)
with 10% fetal bovine serum and 0.1% penicillin/streptomycin as complete growth medium for
several days at 37 oC and 5%CO2 to reach confluence. Each cell type was then plated onto 96
well plates, at 50,000 cells per well at a volume of 150 ul with the respective complete growth
medium. The cells were counted using a hemocytometer and then incubated for 24 hours at 37 oC
under an atmosphere of 5% CO2.
The test emulsion was diluted using the complete growth medium for each cell type, and added
into the wells of each test plate to give a final concentration of N-acryloylciprofloxacin of 2
mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml, and 0.0625 mg/ml within a series. The
testing was done in triplicate and one well in each triplicate was left untreated as the negative
control for 100% growth. The plates were further incubated and monitored for 48 hours at 37 oC
under an atmosphere of 5% CO2. A 5 mg/ml solution of 3-(4,5-dimethyl-2-thiazolyl)-2,5-
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diphenyltetrazolium bromide (MTT) in sterile phosphate-buffered saline (PBS) was added to
give a 10% final concentration in each well. The plates were then further incubated for 4 hours at
37oC under an atmosphere of 5% CO2 to allow for the formation of the purple crystals of 1-(4,5dimethylthiazol)2-yl)-3,5-diphenylformazan. The liquid was then aspirated from each well and
100 µl of dimethylsulfoxide (DMSO) was added to each well, and gently shaken for 1 min to
allow for complete dissolution of the crystals. The IC 50 value for the assay was determined using
a BioTek Synergy H1 hybrid plate reader at both 595 nm and 630 nm. The IC 50 was determined
as the well with at least 50% cell viability compared to the untreated control cell with 100% cell
growth.
Results
Poly(N-acryloyl ciprofloxacin) nanoparticle emulsions were successfully prepared by
modification of the previously reported emulsion polymerization methodology. The main
difference with this new procedure was the pre-solubilization of the water-insoluble antibacterial
agent in an organic solvent to permit more uniform addition into the aqueous solution, in order to
form homogeneous emulsions. We found that dichloromethane provided the best combination of
solubilizing the ciprofloxacin monomer and being volatile enough to evaporate from the media
during emulsion polymerization at 900C.
We also found that the increased temperature (900C rather than 750C), stir speed (1100 rpm
rather than 750 rpm), and the addition of sodium dodecyl sulfate before the monomers were
added provided more optimal results. Additionally, we found it advantageous to let the reactions
run for 48 hours rather than the usual 6 hours required for the butyl acrylate-styrene co-monomer
systems.
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As Figure 4 demonstrates, the dynamic light scattering confirmed the presence of a major
population of nanoparticles in the emulsion, measuring approximately 970 nm in diameter, with
a general trend of increasing size as the amount of N-acryloyl ciprofloxacin is increased from 1%
to 10% in forming the polymer emulsions. In addition, the zeta potential measurements show that
the particles carry a rather high surface charge of -63 (+ 5.6) mV, indicative of the stability of the
emulsion. It is notable that these homo(ciprofloxacin acryloyl) nanoparticles are much larger
than those previously constructed with butyl acrylate-styrene co-monomers, which routinely
measured 45-50 nm in diameter. The basis for this 20-fold increase in size is not apparent at this
time.
(INSERT FIG4.DOCX)
The in vitro antibacterial studies showed that the nanoparticle emulsion was strongly bioactive,
with an MIC of 0.5 µg/ml for S. aureus and 0.012 µg/ml against E. coli. These values are
identical to those of ciprofloxacin itself. The finding that these nanoparticles show antibacterial
capabilities at all against both the gram-positive S. aureus and the gram-negative E. coli was
surprising, given the large dimensions of the particles, and the fact that the active antibacterial
agent is chemically attached to the nanoparticle matrix.
Ciprofloxacin must enter the bacterial cell to arrive at its target, bacterial DNA gyrase, and bind
within the gyrase tertiary structure.
Attachment of ciprofloxacin to the polymer backbone of the nanoparticle presumably requires
hydrolysis of the amide linkage, prior to interaction with DNA gyrase. This occurs either outside
of the cell, or within the bacterium itself if the nanoparticle can enter. Most likely this requires
enzymatic involvement, as the amide functionality is a difficult one to cleave otherwise. The
details of if and how this occurs within bacterial cells requires further investigation that is
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beyond the immediate scope of this study. The in vitro cytotoxicity results for both human
colorectal carcinoma cells HCT-116 and human embryonic kidney cells HEK-293 were also
highly promising. The observed IC50 was 500 µg/ml for both cell lines, a 1000-fold difference
over the bacterial MIC value for S. aureus and greater than 40,000 fold for E. coli.
Lyophilization of the nanoparticle emulsion produced an amorphous powder that could not be
reformulated back to its original emulsified state through addition of water. Moreover, the
resulting powder remained insoluble in organic solvents including methanol, ethanol,
dichloromethane, hexane, acetone, ethyl acetate, and dimethylformamide. We did note that
extraction of the solid material with methanol, ethanol, dichloromethane, hexane, acetone, and
ethyl acetate failed to show any trace of unreacted N-acryloylciprofloxacin upon evaporation and
analysis by proton NMR spectroscopy. This confirms that the polymerization is complete, and
thus all of the ciprofloxacin is incorporated into the framework of the nanoparticle. Attempts to
perform the emulsion polymerization procedure on the free ciprofloxacin instead of the Nacryloyl derivative led to a bilayer mixture, not an emulsion, with the layers separating within
seconds. Additionally we attempted the same procedure using N-acetylciprofloxacin as an analog
similar in structure but without the requisite olefin. Once again, we obtained only an unstable
mixture that separated into layers within a few seconds. Therefore, the acryloyl group is a
prerequisite for emulsification, and for nanoparticle formation.
Though the field of antibacterial polymers is well explored, typically they rely on the use of comonomers in organic media.8-10 This is the first case of an aqueous nanoparticle polymer
emulsion being formed from a single monomer that carries the antibiotic agent itself. We hope to
further investigate the properties of these and other types of antibiotic nanoparticle emulsions to
expand the methodology for delivery and effective treatment of drug-resistant infections.
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Figure Legends

Figure 1
Scheme for dimer based polymerization emulsions.

Figure 2
Scheme for synthesis of N-acryloylciprofloxacin.

Figure 3

Size of Nanoparticles (nm)
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Size of nanoparticles in emulsion vs the % concentration of N-acryloylciprofloxacin.
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